09/20 /2017 Page 1 of 61   A Phase II Trial for the Prevention of G astrointestinal Toxicity from T otal Body 
Irradiation or High Dose Chemotherapy with P asireotide  
 
  
Principal Investigator:  
 [INVESTIGATOR_367527], MD  
Duke  University Medical Center   
DUMC Box 3961  
Durham, NC  [ZIP_CODE]  
Phone: 919- 668-5710  
Fax: 919- 668-1091  
  
Co-Investigators : 
 Nelson Chao, MD, MBA  
Cristina Gasparetto, MD  
Mitchell Horwitz, MD  
Gwynn Long, MD  
Ashley Morris  Engemann, PharmD  
David Rizzieri, MD  
Stefanie Sarantopoulus, MD, PhD  
Keith Sullivan, MD  
Richard Lopez , MD  
Daniel Wild, MD   
Study Statistician :  
Zhiguo Li, Ph.D.  
  Duke IRB Protocol: 00051736   
Study Registry ID: [REMOVED]  
  
09/20 /2017 Page 2 of 61   TABLE OF CONTENTS  
 
1 ABBREVIATIONS  .................................................................................................... 5  
2 OBJECTIVES  ........................................................................................................... 5  
2.1 Primary Objective:  ............................................................................................................................................. 5  
2.2 Secondary Objectives:  ...................................................................................................................................... 5  
2.3 Exploratory Objectives:  ..................................................................................................................................... 5  
3 ENDPOINTS  ............................................................................................................. 6  
3.1 Primary Endpoint  ............................................................................................................................................... 6  
3.2 Secondary Endpoints  ........................................................................................................................................ 6  
3.3 Exploratory Endpoints  ....................................................................................................................................... 6  
4 BACKGROUND AND RATIO NALE FOR USE OF PASI REOTIDE  ......................... 6  
5 DESCRIPTION OF PASIREOTIDE  .......................................................................... 8  
5.1 Mechanism  of Action  ......................................................................................................................................... 9  
5.2 Pharmacodynamics  ......................................................................................................................................... 10 
5.3 Pharmacokinetics  ............................................................................................................................................ 10 
5.4 Absorption and Distribution  ............................................................................................................................ 10 
5.5 Metabolism and Excretion  .............................................................................................................................. 11 
5.6 Steady -state pharmacokinetics  ..................................................................................................................... 11 
5.7 Special Populations  ......................................................................................................................................... 11 
5.8 Hepatic impairment  ......................................................................................................................................... 11 
5.9 Renal impairment  ............................................................................................................................................ 12 
5.10  Pediatric Patients ............................................................................................................................................. 12 
5.11  Geriatric patients  ............................................................................................................................................. 12 
5.12  Drug Interaction Studies:  ................................................................................................................................ 12 
6 NONCLINICAL TOXICOLOGY  .............................................................................. 12 
6.1 Carcinogenesis  ................................................................................................................................................ 12 
6.2 Mutagenesis  ..................................................................................................................................................... 12 
6.3 Impairment of Fertility ..................................................................................................................................... 12 
7 CLINICAL STUDIES  .............................................................................................. 13 
7.1 Clinical Studies in Children  ............................................................................................................................ 15 
7.2 Geriatric Use  .................................................................................................................................................... 15 
8 STUDY DRUG INFORMATION  .............................................................................. 15 
8.1 Dosage  .............................................................................................................................................................. 15 
8.2 Renal or hepatic insufficiency:  ....................................................................................................................... 15 
8.3 Storage and Handling  ..................................................................................................................................... 16 
8.4 Adverse Events  ................................................................................................................................................ 16 
8.5 Drug Interactions  ............................................................................................................................................. 19 
8.5.1  Effects of Other Drugs on Pasireotide  ................................................................................................. 19 
09/20 /[ADDRESS_770190] Elevations  .............................................................................................................................. 21 
8.7.5  Cholelithiasis  ............................................................................................................................................ 22 
8.7.6  Monitoring for Deficiency of Pi[INVESTIGATOR_585636]  ................................................................................ 22 
9 PATIENT ELIGIBILITY  .......................................................................................... 22 
9.1 Inclusion Criteria  .............................................................................................................................................. 22 
9.2 Exclusion Criteria  ............................................................................................................................................. 22 
9.3 Patient Numbering  ........................................................................................................................................... 24 
10 MAT ERIAL AND DATA  ......................................................................................... 24 
11 TREATMENT PLAN AND M ODIFICATIONS  ........................................................ 25 
11.1  Study Design:  ................................................................................................................................................... 26 
11.2  Video Capsule Endoscopy  ............................................................................................................................. 26 
11.3  Biomarker Assays  ........................................................................................................................................... 27 
11.3.1 Citrulline assay  ......................................................................................................................................... 27 
11.3.2 Calprotectin assay  ................................................................................................................................... 27 
11.4  Dose Modifications and Treatment Interruptions/Discontinuation. ........................................................... 28 
11.5  Study Withdrawal  ............................................................................................................................................. 29 
12 ANTICIPATED TOXICITIES. .................................................................................. 29 
12.1 Myelosuppression:  ........................................................................................................................................... 30 
12.2 Gastrointestinal:  ............................................................................................................................................... 30 
12.3 H yperglycemia  .................................................................................................................................................. 30 
12.4 Cardiac:  ............................................................................................................................................................. 30 
12.5 Pulmonary:  ........................................................................................................................................................ 30 
12.6 Hepatic:  .............................................................................................................................................................. 31 
12.7 Renal:  ................................................................................................................................................................. 31 
12.8 GVHD:  ................................................................................................................................................................ 31 
12.9 Neurologic:  ........................................................................................................................................................ 31 
12.10 Miscellaneous:  ................................................................................................................................................ 31 
13 DATA MANAGEMENT AND DATA SAFETY MONITORI NG ................................ 32 
13.1  Data Management  ........................................................................................................................................... 32 
13.1.1  Electronic Case Report Forms (eCRFs)  .............................................................................................. 32 
13.1.2 Data Management Procedures and Data Verification  ........................................................................ 32 
13.1.3 Study Closure  ........................................................................................................................................... 33 
13.2  Data Safety Monitoring  ................................................................................................................................... 33 
14 SAFETY AND STUDY DATA MONITORING .......................................................... 33 
14.1  Safety  ................................................................................................................................................................ 33 
14.1.1 Adverse Event Reporting.  ....................................................................................................................... 33  
14.1.2 SAE Reporting  .......................................................................................................................................... 35 
09/20 /2017 Page 4 of 61   14.1.3 Pregnancy  ................................................................................................................................................. 36 
14.2  Data Monitoring:  .............................................................................................................................................. 37 
15 STA TISTICAL CONSIDERATI ONS  ......................................................................... 37 
15.1  Objectives  ......................................................................................................................................................... 38 
15.1.1 Primary Objective:  .................................................................................................................................... 38 
15.1.2 Secondary Objectives:  ............................................................................................................................ 38 
15.2  Exploratory Objectives:  ................................................................................................................................... 38 
15.3  Endpoints:  ......................................................................................................................................................... 38 
15.3.1 Primary Endpoint  ...................................................................................................................................... 38 
15.3.2 Secondary Endpoints  .............................................................................................................................. 39 
15.3.3 Exploratory Endpoints  ............................................................................................................................. 39 
15.4  Stoppi[INVESTIGATOR_1869] ................................................................................................................................................. 39 
16  REFERENCES  ....................................................................................................... 41 
APPENDIX A: ST UDY CALENDAR FOR SPECIAL STUDIES  ................................... 43 
APPENDIX B: CAPSULE ENDOSCOPY PREPARATIO N INSTRUCTIONS  .............. 45 
APPENDIX C: GUIDANCE  FOR HYPERGLYCEMIA M ANAGEMENT  ....................... 47 
APPENDIX D: QT PROLO NGING MEDICATIONS (INEXHAUSTIVE)  ........................ 48 
APPENDIX E: STUDY DRUGS AND EXAMPLE PREP ARATORY REGI MENS  ......... 50 
E1.  Total Body Irradiation  ...................................................................................................................................... 50 
E2. Busulfan (Myerlan) NSC #750  ....................................................................................................................... 50 
E3. Cyclophosphamide (Cytoxan, CTX) NSC #[ZIP_CODE]  ..................................................................................... 50 
E4. Cyclosporine (Sandimmune)  ......................................................................................................................... 51 
E5. Methotrexate (MTX)  ........................................................................................................................................ 52 
E6. Example Schedule  ............................................................................................................................................. 54 
APPENDIX F: ACUTE GVHD SCORING  ..................................................................... 55 
APPENDIX G: CHRONIC GVHD SCORING  ................................................................ 56 
 
APPENDIX H: SAE COVERSHEETS…………………………… ...………………………. 60 
  
09/20 /[ADDRESS_770191] Stem Cell Transplantation  
TBI Total Body Irradiation  
VCE V ideo Capsule Endoscopy  
  
2 OBJECTIVES  
  2.1 P rimary  Objective :  
To evaluate the efficacy and safety of pasireotide in mitigating GI toxicity from the 
preparatory regimens for allogeneic stem cell transplantation.   
 2.2 S econdary  Objective s:   
To evaluate the efficacy of p asireotide in reducing the incidence and severity of  acute 
GVHD at [ADDRESS_770192] -transplant to historical controls.   
 Historical controls will be drawn from a group o f patients matched for age, disease, graft 
source, preparatory regimen, GVHD prophylaxis, and number of prior therapi[INVESTIGATOR_585637].    
 2.3 Exploratory Objectives:  
To evaluate plasma citrulline and fecal calprotectin levels as biomarkers of GI tract health and function in SCT patients.  
 To evaluate GI toxicity assessments by [CONTACT_585670] . 
  
09/20 /[ADDRESS_770193] patients  who are treated 
with pasireotide, based on CTCAE 4.0 criteria , through transplant day 30.  
 3.2  Secondary Endpoint s 
The secondary endpoint s will be : 
• Incidence and maximum severity of Acute GVHD at  [ADDRESS_770194]-transplant . 
• Incidence and maximum severity of Chronic GVHD at [ADDRESS_770195] -transplant . 
• Rate of overall survival at [ADDRESS_770196] -transplant . 
• Rate of Disease free survival at [ADDRESS_770197]  
(Dr.Wild) . 
  4 BACKGROUND AND RATIONALE  FOR USE OF PASIREOTIDE  
  Total body irradiation (TBI) or high dose busulfan is a standard preparatory regimen for 
the treatment of hematological disease prior to stem cell transplantation. Unfortunately, these approaches are associated with significant acute and chronic toxicities, and injuries to the bone marrow and gastrointestinal (GI) tract are the main determinants of lethality after total -body irradiation (TBI) [ 1, 2]. Specifically, the use of this modality 
results in acute gastrointestinal toxicity such as nausea, vomiting and diarrhea. The inflammatory response is also likely important in setting up the appropriate milieu for the induction of graft versus host disease (GVHD). Some progress has been made in the management of radiation injury  of the hematopoietic/immune system. However, 
effective and safe countermeasures against structural injury and dysfunction in the GI tract remain an unmet need [2]. 
 In the intestine, radiation damages crypt stem cells and proliferating transit cells, thereby [CONTACT_585671][INVESTIGATOR_585638] [ 3]. Among the various intraluminal factors, pancreatic 
enzymes exert a particularly prominent influence on development of intestinal radiation toxicity  [4]. Hence controlling pancreatic enzyme secretion has been explored as a 
09/20 /2017 Page 7 of 61   method to attenuate acute mucosal injury and increases survival after abdominal 
irradiation [ 5, 6]. 
 Efforts to counter the GI toxicity have included drugs such as keratinocyte growth factor (KGF) that has been shown to decrease mucositis associated with TBI. Unfortunately, the data with KGF is relatively marginal and this drug has not been universally accepted into routine clinical use.  Somatostatin analogs are known as inhibitors of growth hormone (GH) and other hormones (including gastro- intestinal hormones) and, among 
many different activities that influence the GI tract, inhibit the secretion of pancreatic enzymes into the bowel lumen [ 7, 8]. Earlier studies showed that the “ prototype” 
somatostatin analog, octreotide, markedly ameliorated mucosal injury in the small bowel after localized irradiation [ 9]. Subsequent randomized clinical trials have translated this 
to patients with severe radiation- induced GI toxicity, thus confirming therapeutic efficacy 
in humans  [10]. 
 While octreotide can be used in the clinical situation to reduce side effects of radiation therapy, its short half -life is a serious limitation in situations where intravenous or 
multiple subcutaneous (s.c .) administrations are not logistically feasible. A more recently 
developed synthetic somatostatin analog, SOM230 (pasireotide,  Pasireotide), however, 
has much greater metabolic stability and thus circumvents this obstacle [ 11]. It was also 
reported in [ADDRESS_770198] cytoprotective effects on the bone marrow or the intestine [ 12]. Hence, while post -TBI intestinal crypt survival and 
hematopoietic injury were similar, the intestinal barrier was structurally and functionally preserved. Moreover, protection was reversed by [CONTACT_3252]- administration of pancreatic 
enzymes, thus strongly suggesting that reduced secretion of proteolytic enzymes into the bowel lumen was the mechanism of action [ 12].   
 

09/20 /[ADDRESS_770199] of SOM230 administration on mucosal surface area. Panel A: TBI (8 
Gy) induced a reduction in mucosal surface area. SOM230 administration significantly diminished the radiation- induced decrease in mucosal surface area (P < 10−6) (n = 6). 
Panel B: Representative image of intestine from a vehicle- treated animal on day 3.5 
after 8 Gy TBI. Panel C: Representative image of intestine from an SOM230- treated 
animal on day 3.5 after 8 Gy TBI. SOM230: 0.5 mg/kg b.i.d.  
 The beneficial effects of SOM230 were seen even when administered as late as 24 hrs. after total body irradiation.  
 
 
Figure 2.  Dose -dependent radiation- mitiga ting effects of SOM230. Kaplan- Meier 
survival curves from mice exposed to 8.5, 9 and 9.5 Gy radiation (SOM230 administration beginning 24 h after TBI). SOM230 significantly reduced lethality in a dose- dependent manner across radiation doses (P < 0.0001). n = 8. 
 Pasireotide has recently been  approved for the treatment of adult patients with 
Cushing’s disease for whom pi[INVESTIGATOR_585639].  Pasireotide, with its ability to perform a near complete chemical pancreatectomy , is an 
excellent candidate for mitigation of the toxicities associated with TBI or high dose chemotherapy. The impact on the GI tract is likely related to pasireotide’s ability to  block 
the somatostatin receptor sst 2 leading to the cessation of export of  pancreatic 
enzymes. Moreover, its advanced development as an agent for mitigation of GI 
toxicities after unplanned radiation exposure further adds excitement for its use in a clinical trial.   
  5 DESCRIPTION OF PASIREOTIDE  
  Pasireotide (pasireotide)  injection  is prepared as a st erile solut ion of pasireotide 
diaspartate  in a tartaric  acid  buffer  for a dministration  by [CONTACT_63275].  
Pasireotide is a som atostatin  analog.  Pasireotide diaspartate,  chemically  know n as (2-
Aminoet hyl) carbamic acid (2R,5S,8S,11 S,14R ,17S,19aS) -11-(4-aminobu tyl)-5-benzyl-
8-(4-benzyl oxybenzyl) -14- (1H-indol -3-ylm ethyl)-4,7,10,13,16,19- hexaoxo-17-
phenyloctadecahydro- 3a,6,9,12,15,18- 
hexaaz acyclopentacyclooctadecen-2-yl ester, 
di[(S)-2-aminosuccinic acid] salt, is a cyclohexapeptide with pharm acologic properties  
mimicking  those of the natur al hormone somatostatin.  
 

09/20 /2017 Page 9 of 61   The mole cular formula of pasireotide  diaspartate is C58H66N10O9 • 2 C 4H7NO 4 and the 
molecular  weight  is 1313.41.   
 
The structural  formula is: 
 
 
 
 
Pasireotide i s supplied  as a sterile  solution  in a single -dose, 1 mL co lorless  glass  
ampule containing  pasireotide in 0.3 mg/mL, 0.6 mg/mL, or 0.9 mg/mL strengths  for 
subcutaneous  injection.  
 
Each glass am pule contai ns:   
 
 0.3 mg 0.6 mg 0.9 mg 
Pasireotide  
 0.376 2* 0.7524* 1.1286* 
Mannitol  49.50 49.50 49.50 
Tartaric  acid 1.501 1.501 1.501 
Sodium  hydroxide  ad pH 4.2 ad pH 4.2 ad pH 4.2 
Water  for injection  ad 1ml ad 1ml ad 1ml 
* corresponds  to 0.3/0.6/0.9 mg pasireotide base 
 Note:  Each  ampule conta ins an overfill of 0.1ml to allow  accurate a dministration  of 1 ml 
from the ampule.  
 5.1 Mechanism  of Action 
Pasireotide is an injectable  cyclohexapep tide somatostatin  analogue. Pasireotide  
exerts  its pharmacological  activity  via binding  to somatostatin receptors. Five human 
somatostatin receptor  subtypes  are known:  sst 1, 2, 3, 4, and 5. 
 

09/20 /2017 Page 10  of 61   These  receptor  subtyp es are expressed in different  tissues under normal physio logical  
conditions.  Pi[INVESTIGATOR_585640] s from  Cushing ’s disease patients  frequently  
over-express sst5 wher eas the other  receptor  subtypes  are often not expressed or  are 
expressed at lower  levels.  Pasireot ide binds  and activates  the sst receptors  resulting in 
inhibition  of ACTH secretion,  which  leads  to decreased cortisol secretion.  
 
The bindi ng affinities  of endogen ous somatostatin and pasireotide are shown  in Table 2. 
 
Table  2- Binding affiniti es of somatostatin  (SRIF -14) and pasireotide  to the five 
human sst receptor  subtypes  (hsst1 -5) 
 
Compound  hsst1  hsst2  hsst3  hsst4  hsst5  
Somatostatin  (SRIF -14) 0.93±0.12 0.15±0.02 0.56±0.17 1.5±0.4 0.29±0.04 
Pasire otide 9.3±0.1 1.0±0.1 1.5±0.3 > 1000 0.16±0.01 
Results are the mean±SEM  of IC50 values expres sed as  nmol/l 
 5.2 Pharmacodynamics  
Cardiac Electrophysiology  
QTcF interval was evaluated in a randomized, blinded, crossover study in healthy 
subjects investigating pasireotide doses of 0.6 mg b.i.d. and 1.95 mg b.i.d. The maximum mean (95% upper confidence bound) placebo- subtracted QTc F change from 
baseline was 12.7 (14.7) ms and 16.6 (18.6) ms, respectively. Both pasireotide doses decreased heart rate, with a maximum mean (95% lower confidence bound) placebo-subtracted change from baseline of - 10.9 ( -11.9) beats per minute (bpm) observed at 
1.5 hours for pasireotide 0. 6 mg bid, and - 15.2 ( -16.5) bpm at 0.5 hours for pasireotide 
1.95 mg b.i.d. The supra- therapeutic dose (1.95 mg b.i.d. ) produced mean steady -state 
Cmax values 3.3- fold the mean Cmax for the 0.6 mg b.i.d . dose in the study.  
 5.3 Pharmacokinetics  
In healthy volunteers, pasireotide demonstrates approximately linear pharmacokinetics (PK) for a dose range from 0.0025 to 1.5 mg. In Cushing’s disease patients, pasireotide demonstrates linear dose- exposure relationship in a dose range from  0.[ADDRESS_770200] is unlikely to occur since p asireotide  is administered via a 
parenteral route.  
 In healthy volunteers, pasireotide is widely distributed with large apparent volume of distribution (Vz/F >100 L). Distribution between blood and plasma is concentration independent and shows that pasireotide is primarily located in the plasma (91%). Plasma protein binding is moderate (88%) and independent of concentration.  
 
09/20 /2017 Page 11  of 61   Pasireotide has low passive permeability  and is likely to be a substrate of P -gp (P -
glycoprotein), but the impact of P -gp on ADME (absorption, distribution, metabolism, 
excretion) of pasireotide is expected to be low. Pasireotide is not a substrate of efflux 
transporter BCRP (breast cancer resistance protein), influx transporter OCT1 (organic cation transporter 1), or influx transporters OATP (organic anion- transporting 
polypeptide) 1B1, 1B3, or 2B1.  
 5.5 Metabolism  and Excretion  
Pasireotide was shown to be metabolically stable in human liver and kidney microsomes systems. In healthy volunteers, pasireotide in its unchanged form is the predominant form found in plasma, urine and feces. Somatropin  (growth hormone)  may 
increase CYP450 enzymes and, therefore, suppression of growth hormone secretion by [CONTACT_585672]450 enzymes.  
 Pasireotide is eliminated mainly via hepatic clearance (biliary excretion) with a small contribution of the renal route. In a human ADME study 55.9 ± 6.63% of the radioactivity dose was recovered over the first [ADDRESS_770201] dosing, including  
48.3 ± 8.16% of the radioactivity in feces and 7.63 ± 2.03% in urine.  
 The clearance (CL/F) of pasireotide in healthy volunteers and Cushing’s dise ase 
patients is ~7.6 liters/h and ~3.8 liters/h, respectively.  
 5.6 Steady -state pharmacokinetics  
Following multiple subcutaneous doses, pasireotide demonstrates linear pharmacokinetics in the dose range of 0.05 to 0.6 mg once a day in healthy volunteers, and 0.3 mg to 1.2 mg twice a day in Cushing’s disease patients. Based on the 
accumulation ratios of AUC, the calculated effective half -life (t1/2,eff) in healthy 
volunteers was approximately 12 hours (on average between 10 and 13 hours for 0.05, 0.2 and 0.6 mg  once a day doses).  
 5.[ADDRESS_770202] pasireotide pharmacokinetics and there is no meaningful difference in pharmacokinetics between Caucasian and non- Caucasian PK parameters.  
 5.8 Hepatic impairment  
In a clinical study in subjects with im paired hepatic function (Child -Pugh A, B and C), 
subjects with moderate and severe hepatic impairment (Child- Pugh B and C) showed 
significantly higher exposures than subjects with normal hepatic function. Upon comparison with the control group, AUCinf was increased by 12%, 56% and 42% and Cmax increased by 3%, 46% and 33%, respectively, in the mild, moderate and severe hepatic impairment groups.  
 
09/20 /[ADDRESS_770203] the circulating levels of pasireotide [see Use in Specific Populations (8.7)].  
 5.[ADDRESS_770204] been performed in geriatric patients.  
 5.12 Drug Interaction Studies:  
There was no significant drug interaction between pasireotide and metformin, nategli nide or liraglutide.  
 5.13 Rationale for dose in this study:  
In a phase III study of Cushing's Disease ([SOM230B2216] and [SOM230B2124] patients randomized to 0.6 mg bid and 0.9 mg bid, adverse events were similar between doses (Table 1, page 18). Therefore, in  order to maximize the potential for clinical 
efficacy, and because we do not think there would be a significant difference in toxicity, we chose to use 0.9 mg bid as the starting dose. If significant toxicities occur, we could consider reducing to 0.6 mg bid, but we believe there is sufficient safety data to justify 0.9 mg bid as the starting dose.  
  6 NONCLINICAL TOXICOLOGY  
  6.1 Carcinogenesis  
A life -time carcinogenicity study was conducted in rats and transgenic mice. Rats were 
given daily subcutaneous doses of pasireotide at 0.01, 0.05, 0.3 mg/kg/day for 104 weeks. There were no drug -related tumors in rats at exposures up to 7- fold higher than 
the maximum recommended clinical exposure at the 1.8 mg/day dose. Mice were given subcutaneous doses of pasireotide at 0.5, 1.0, 2.5 mg/kg/day for 26 weeks and did not identify any carcinogenic potential.  
 6.2 Mutagenesis  
Pasireotide was not genotoxic in a battery of in vitro assays (Ames mutation test in Salmonella and E coli. and mutation test in human peripheral lymphocytes). Pasireotide was not genotoxic in an in vivo rat bone marrow nucleus test.  
6.3 Impairment of Fertility  
 Subcutaneous dosing at 0.1 mg/kg/day before mating and continuing into gestation in rats at exposures less than the human clinical exposure based on body surface area comparisons across species resulted in statistically significant increased implantation 
09/20 /2017 Page 13  of 61   loss and decreased viable fetuses, corpora lutea, and implantation sites. Abnormal 
cycles or acyclicity were observed at 1 mg/kg/day (5- fold higher than the maximum 
therapeutic exposure based on surface area, comparisons across species).  
  7 CLINICAL  STUDIES  
  A Phase  III, multicenter,  random ized study  was conducted to evaluate the safety and 
efficacy of two dose  levels  of pasireotide ov er a 6-m onth treatment period in Cushing ’s 
disease patients  with persistent  or recurrent  disease despi[INVESTIGATOR_585641] y. 
 Patients  with a baseline 24-hour urine free cortisol (UFC)  >1.5 x upper  limit of normal 
(ULN) were  random ized to receive  
a pasireotide dosage of either  0.6 mg subcutaneous  
b.i.d. or 0.9 mg subcutaneous  b.i.d. After  three months  of treatment, patients  with a 
mean 24-hour UFC ≤ 2.[ADDRESS_770205] and b elow or equal  to their baseline values  continued  
blinded treatment at the  rando mized dose until Month 6. Patients who did not meet these  
criteria  were  unblinded  and the dose was increased by 0.3 mg b.i.d. After  the initial six 
months  in the study,  patients entered an additional  6-month open- label  treatment period. 
The dosage could  be reduced  by 0.3  mg b.i.d. at any time during  the study  for 
intolerability. 
 A to
tal of 162 patients  were  enrolled in this study. The majority  of patients  were  female 
(78%) and had persistent  or recurrent  Cushing’s disease despi[INVESTIGATOR_585642]  (83%)  
with a mean age of 40 years.  A few patients  (4%) in either treat ment  group  received  
previous  pi[INVESTIGATOR_585643].  The m edian value of the baseline 24-hour UFC for all 
patients  was 565 nmol/24  hours  (normal range  30 to 145 nmol/24  hours).  About two-
thirds  of all rando mized patients  completed  six months  of treatment. 
 
The primary efficacy endp oint was the proporti on of patients  who achieved normalization  
of mean  24-hour UFC levels after  six months  of treatment and did not dose  increase  
during  this period.  
 
24-Hour  Urinary  Free Cortisol  Resu lts 
 
At Month 6, the percentages  of responders  for the primary  endpoint were  15% and 26% 
in the 0.6 mg b.i.d. and 0.9 mg b.i.d.  groups, respectively  (Table 3). The percentages  of 
patients  with mUFC ≤ ULN or ≥ 50% reduction from baseline,  a less  stringent  endpoint  
than the primary endpoi nt, were  34% in the 0.6 mg bid and 41% in the 0.[ADDRESS_770206] on 24-hour UFC r esponse.  
Mean and median percentage changes  in UFC from baseline are presented  in Table  3. 
    
 
09/20 /2017 Page 14  of 61   
Table  3- 24-Hour  Urina ry Free  Cortisol (UFC)  Study  Results  at 
Month  6 in Patients  with Cushing’s  Disease  
 Pasireotide  
0.6 mg b .i.d. 
N=82 Pasireotide  
0.9 mg b .i.d. 
N=80 
UFC R esponders n/N  
% (95%  CI) 12/82 
15% (7%, 22%) 21/80 
26% (17%, 36%) 
   
UFC Levels 
(nmol/24hr) 
Baseline  N=78 N=72 
Mean (SD) 868 (764) 750 (930) 
Median 704 470 
   
% Change from  
baseline M ean 
(95% CI) 
Median -22% (-44%, +1%) 
-47% -42% (-50%, -33%) 
-46% 
 
Pasireotide resulted in a decrease in the mean 24- hour UFC after 1 month of treatment 
(Figure 1). For patients (n=78) who stayed in the trial, similar UFC lowering was observed at Month 12.  
  Figure 1 - Mean 
(±SE) Urinary Free Cortisol (nmol/24h) 
at time points up to Month 6 by [CONTACT_585673]: On ly patients 
who comp leted 6 
months of treatment are inc luded in t his an alysis (n =110). The reference line is t he 
upper limit of no rmal for UFC,  which is 1 45 nmol/2 4hour; +/-Standar d erro rs are 
displayed. 
 
Other endpoints  
 
Decreases from baseline for blood pressure were observed at Month 6, including patients who did not receive any antihypertensive medication. However, due to the fact 
09/20 /[ADDRESS_770207] 
circumference were 4.4 kg, 1.6 kg/m2 and 2.6 cm, respectively. Individual patients showed varying degrees of improvement in Cushing's disease manifestations but because of the variability in response and the absence of a control group in this trial, it is uncertain whether these changes could be ascribed to the effects of p asireotide. 
 7.[ADDRESS_770208] not been established in pediatric patients.  
 7.2 Geriatric Use  
Clinical studies of p asireotide  did not include sufficient numbers of patients aged 65 and 
over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the 
elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy . 
  8 STUDY DRUG INFORMATION 
  8.1 Dosage  
The dose of p asireotide to be used in this study i s 0.9 mg by [CONTACT_306838] 12 hours .  It will be supplied in 0.9 mg/mL in a single- dose, 1 mL colorless glass 
ampules.  
 It is expected that patients will receive their pasireotide injections in the hospi[INVESTIGATOR_585644]. However, for patients who are no t admitted 
and receive their pasireotide at home (e.g. the night before admission for conditioning), they will be taught by [CONTACT_585674] -administer pasireotide. As a 
subcutaneous injection, this process is similar to giving self -injections of insulin and is 
done routinely by [CONTACT_585675]’s who are receiving pasireotide. Note that this does not apply to the first dose: as per protocol, all first doses of pasireotide will be given by [CONTACT_585676][INVESTIGATOR_585645] m onitoring.  
 8.2 Renal or hepatic insufficiency:  
No dosage adjustment of p asireotide in patients with impaired renal function is required.  
 Dose adjustment is not required in patients with mild impaired hepatic function (Child-Pugh A) .   P atients with moderately impaired hepatic function (Child- Pugh B). and 
severe hepatic impairment (Child- Pugh C)  will be excluded from the study . 
09/20 /2017 Page 16  of 61    
8.3 Storage and Handling  
Store at 25° C (77°F); excursions permitted to 15° -30°C (59° -86°F), protect from light.  
 8.[ADDRESS_770209]  the rates  observed in practice.  Of note, 
pasireotide has not been studied in children and the below data are from trials in adults.  
 A total of 162 Cushing ’s disease patients  were  exposed to pasireotide in the Phase III 
study.  At study  entry, patients  were rando mized to receive  twice  a day (b.i.d.) doses  of 
either  0.6 mg or 0.9 mg of pasireotide given subcutaneously.  The mean age of patients  
was approximately  40 ye ars old with a predom inance of female patients  (78%). The 
majority  of the patients  had persiste nt or recurrent  Cushing ’s disea se (83%)  and few 
patients  (≤ 5%) in either  treatment  group  had received previous  pi[INVESTIGATOR_585643].  The 
median exposure  to the treatment  was 10.4 months  (0.03 -37.8)  with 68% of patients  
having  at least  six months  exposure.  
 In th
e  Phase III trial, adverse reactions  were  reported  in 98% of patients.  The most  
comm on adverse react ions (frequency  ≥20% in either  group)  were  diarrhea,  nausea,  
hyperg lycemia, cholelithiasis,  headache,  abdo minal pain,  fatigue,  and diabetes  mellitus. 
There  were no deaths  during  the study.  Serious  adverse  events  were  reported in 25% of 
patients. Adverse events leading  to study discont inuation were  reported in 17% of 
patients.  
 Adverse reactions  with an overall  frequency higher than 5% are presented in Table  
[ADDRESS_770210]. 
 Table  1 - Adverse reac tions  [n (%)] with an  overall frequency of mo re than  5% in 
the combined  dose  group in the Phase III study in Cushing’s  disease patients 
 
 Pasireotide  
0.6 mg b id 
N=82 Pasireotide  
0.9 mg b id 
N=80 Overall 
N=162 
Diarrhea  48 (59) 46 (58) 94 (58) 
Nausea 38 (46) 46 (58) 84 (52) 
Hyperglyce mia 31 (38) 34 (43) 65 (40) 
Cholelithiasis 25 (30) 24 (30) 49 (30) 
Heada che 23 (28) 23 (29) 46 (28) 
Abdominal pain  19 (23) 20 (25) 39 (24) 
Fatigue  12 (15) 19(24) 31 (19) 
Diabetes  mellitus  13 (16) 16 (20) 29 (18) 
Injection  site reacti ons 14 (17) 14 (18) 28 (17) 
Nasop haryngitis 10 (12) 11 (14) 21 (13) 
09/20 /2017 Page 17  of 61   Alopecia  10 (12) 10 (13) 20 (12) 
Asthenia 13 (16) 5 (6) 18 (11) 
Glycosylated  hemoglobin increased  10 (12) 8 (10) 18 (11) 
Alanine  aminotran sferase  
id  11 (13) 6 (8) 17 (10) 
Gamma -glutamyl 
transferase increas ed 10 (12) 7 (9) 17 (10) 
Edema periph eral 9 (11) 8 (10) 17 (10) 
Abdominal pain u pper 10 (12) 6 (8) 16 (10) 
Decreased  appetite  7 (9) 9 (11) 16 (10) 
Hypercholeste rolemia 7 (9) 9 (11) 16 (10) 
Hypertension 8 (10) 8 (10) 16 (10) 
Dizziness  8 (10) 7 (9) 15 (9) 
Hypoglycemia 12 (15) 3 (4) 15 (9) 
Type 2 diabetes mellitus 10 (12) 5 (6) 15 (9) 
Anxiety 5 (6) 9 (11) 14 (9) 
Influenza 9 (11) 5 (6) 14 (9) 
Insomnia 3 (4) 11 (14) 14 (9) 
Myalgia  10 (12) 4 (5) 14 (9) 
Arthralgia 5 (6) 8 (10) 13 (8) 
Prurit us 6 (7) 7 (9) 13 (8) 
Lipase in creased 7 (9) 5 (6) 12 (7) 
Constipation  7 (9) 4 (5) 11 (7) 
Hypotension 5 (6) 6 (8) 11 (7) 
Vomiting 3 (4) 8 (10) 11 (7) 
Back  pain 4 (5) 6 (8) 10 (6) 
Dry skin 5 (6) 5 (6) 10 (6) 
Electrocardiogram  QT pro longed  5 (6) 5 (6) 10 (6) 
Hypokalemia 6 (7) 4 (5) 10 (6) 
Pain in extremity 6 (7) 4 (5) 10 (6) 
Sinus  bradycardia 8 (10) 2 (3) 10 (6) 
Vertigo 4 (5) 6 (8) 10 (6) 
Abdominal distension 4 (5) 5 (6) 9 (6) 
Adre nal insufficiency 4 (5) 5 (6) 9 (6) 
Aspartate aminotransferase 
increas ed 6 (7) 3 (4) 9 (6) 
Blood glucose increas ed 6 (7) 3 (4) 9 (6) 
Other  notable  adverse reactions which  occurred with a frequency  less than 5% 
were:  anemia (4%); blood amylase increased (2 %) and proth rombin time 
prolonged (2%).  
 
Gastrointestinal  Disorders  
Gastrointest inal disorders,  predo minantly  diarrhea,  nausea,  abdom inal pain a nd 
vomiting were reported frequent ly in the Phase  III trial (see Table  1). These  events  
09/20 /[ADDRESS_770211] month of treatment with pasireotide  and 
required no intervent ion. 
 
Hyperglycemia and Diabe tes 
Hypergl ycemia -related  terms were reported frequently  in the Phase III trial. For all 
patients,  these  terms included: hyperg lycemia (40%),  diabetes  mellitus  (18%),  
increased HbA1c  (11%),  and type 2 diabetes  mellitus  (9%).  In general, increases  in 
fasting  plasma glucose (FPG) and hemoglobin A1c (HbA1c)  were seen  soon  after 
initiation  of pasireotide  and were  sustained during the treatment period.  In the 
pasireotide 0.6 mg group, mean fasting plasma glucose (FPG) levels  increased from 
98.6 mg /dL at baseline to 125.1 mg/dL at Month 6. In the pasireotide 0 .9 mg group,  
mean  fasting  plasma glucose (FPG) levels  increased from 97.0 mg /dL at baseline to 
128.0 mg/dL at Month 6. In the p asireotide 0.6 mg group,  HbA1c  increased  from 5.8%  
at baseline to 7.2%  at Month 6. In the pasireotide 0.9 mg group,  HbA1c  increased 
from 5.8%  at baseline to 7.3% at Month  6. 
 
At one m onth follow -up vi sits following  discontinuat ion of pasireotide , mean FPG 
and HbA1c  levels  decre ased but rem ained  above baseline values.  Long -term 
follow -up data are not available.  
 
Elevated Liver Tests  
In the Phase  III trial, there were  trans ient mean elevat ions in aminotransferase values  
in patients  treated with pasireotide. Mean  values  returned to baseline  levels  by [CONTACT_43380]  
[ADDRESS_770212]: one patient 
with Cushing’s disease a nd three  healthy  volunteers . In all four cases, the elevations  
were  noted w ithin the first 10 days of treatm ent. In all of these  cases, total bilirubin  
elevations  were  seen  either  concomit antly  or preceding  the trans aminase elevati on. The 
patient with Cushing ’s disease developed jaund ice. All four cases had resolution  of the 
laboratory abnorm alities  with discontinuat ion of pasireotide . 
 
Hypocortisolism  
Cases  of hypocortisolism  were  reported  in the Phase III study  in Cushing ’s disease 
patients.  The majority  of cases were m anag eable by [CONTACT_585677]/or  adding low -dose,  short-term glucocorticoid therapy. 
 
Injection  Site Reactions  
Injection  site reactions  were reported in 17% of patients  enrolled in the Phase III trial 
in Cushing ’s disease.  The events were most frequently  reported as local pain,  
erythema, he matoma, hemo rrhage,  and pruritus.  These events  resolved 
spontaneous ly and requir ed no in tervent ion. 
 
Thyroid function  
09/20 /2017 Page 19  of 61   Hypothyr oidism  with the use of pasireotide  was reported for seven  patients  
participating  in the Phase  III study in Cushing ’s disease.  All seven patients  
presented  with a TSH close to or below  the lower  limit at study  entry  which 
precludes  establishing  a co nclusive  relationship  between the adverse event  and 
the use of pasireotide. 
 
Other  Abnormal  Laborato ry Findings  
Asymptomatic and revers ible elevations  in lipase  and amylase were observed in 
patients  receiving pasireotide in clinic al studies.  Pancreatitis  is a potential  adverse  
reaction asso ciated  with the use of soma tostatin  analogs  due to the association 
between cholelithiasis  and acute  pancreatitis.  
 
For hemoglobin levels,  mean decreases  that rem ained within  normal range were  
observed.  Also,  post-baseline elevations in PT and PTT were  noted in 33% and 47% of 
patients,  respectivel y. The PT and PTT elevations  were  minim al. 
 These  labora tory findings  are of unclear  clinical significance.  
 
8.[ADDRESS_770213] 
additive effects on the prolongation of the QT interval. Caution is required when co-
administering pasireotide with anti -arrhythmic medicines and other drugs that may 
prolong  the QT interval [see Warnings and Precautions (5.3)].  
 
8.5.2  Effects of Pasireotide on Other Drugs  
Cyclosporine 
Concomitant administration of cyclosporine with pasireotide may decrease the relative 
bioavailability of cyclosporine and, therefore, dose adjustment  of cyclosporine to 
maintain therapeutic levels may be necessary  
 
Bromocriptine  
Co-administration of somatostatin analogues with bromocriptine may increase the blood 
levels of bromocriptine. Dose reduction of bromocriptine may be necessary.  
The use of anti coagulant medication should be avoided. Patients currently receiving 
supplemental pancreatic enzymes may be enrolled, but they should not start such treatment or increase the dose while on study.  
 8.6 Contraindications  
None  
   
09/20 /2017 Page 20  of 61   8.7 Warnings  
 
8.7.1  Hypocortisolism  
Treatment with p asireotide leads to suppression of adrenocorticotropic hormone 
(ACTH) secretion in Cushing’s disease. Suppression of ACTH may lead to a decrease 
in circulating levels of cortisol and potentially hypocortisolism.  
 Monitor and instruct patients on the signs and symptoms associated with hypocortisolism (e.g. weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyponatremia or hypoglycemia). If hypocortisolism occurs, consider temporary dose reduction or interruption of treatment with p asireotide, as well as temporary, exogenous 
glucocorticoid replacement therapy.    
 In a phase III study of patients with Cushing’s Disease, adrenal insufficiency was noted in 6% of patients that received a median of 10.4 months of pasireotide therapy (0.9mg BID).  Hypocortisolism is not expected to occur in this trial due to the relatively short duration of treatment. Therefore, cortisol assessment will not be required on this protocol, however, it may be performed at the investigator’s discretion.  
 
8.7.[ADDRESS_770214] been seen in healthy volunteers and patients 
treated with p asireotide. In the Phase III trial, the development of pre- diabetes and 
diabetes was observed [see Clinical Studies (14)]. In this trial, nearly all patients —
including those with normal glucose status at baseline, pre- diabetes, and diabetes —
developed worsening glycemia in the first two weeks of treatment. Cushing’s disease patients with poor glycemic control (as defined by [CONTACT_13505]1c values >8% while receiving anti-diabetic therapy) may be at a higher risk of developi[INVESTIGATOR_585646], e.g. ketoacidosis.  
 Because of this predictable adverse reaction, the glycemic status [fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c)] should be assessed prior to starting treatment with p asireotide. In patients with uncontrolled diabetes , intensive anti -diabetic 
therapy should be initiated prior to treatment with p asireotide. Monitoring of blood 
glucose and/or FPG assessments should be done at baseline , and transplant day 14. 
During pasireotide administrations, patients will typi[INVESTIGATOR_585647].  
 If hyperglycemia develops in a patient treated with pasireotide, the initiation or adjustment of anti -diabetic treatment is recommended. The optimal treatment for the 
management of pasireotide- induced  hyperglycemia is not known. If uncontrolled 
hyperglycemia persists, despi[INVESTIGATOR_177174], the dose of pasireotide should be reduced or discontinued.  
 After treatment discontinuation, glycemic monitoring (e.g. FPG or HbA1c should be 
done according to clinical practice. Patients who were initiated on anti -diabetic therapy 
09/20 /2017 Page 21  of 61   as a result of p asireotide may require closer monitoring after discontinuation of 
pasireotide, especially if the anti -diabetic therapy has a risk of causing hypoglycemia.  
 
8.7.3  Bradycardia and QT Prolongation  
Bradycardia 
Bradycardia has been reported with the use of p asireotide [see Adverse Reactions (6)]. 
Patients with cardiac disease and/or risk factors for bradycardia, such as history of 
clinically significant bradycardia, hi gh-grade heart block, or concomitant use of drugs 
associated with bradycardia, should be carefully monitored. Dose adjustments of beta-blockers, calcium channel blockers, or correction of electrolyte disturbances may be necessary.  
 
QT Prolongation  
Pasireot ide is associated with QT prolongation. In two thorough QT studies with 
pasireotide, QT prolongation occurred at therapeutic and supra -therapeutic doses. 
Pasireotide should be used with caution in patients who are at significant risk of 
developi[INVESTIGATOR_306703], such as those [see Clinical Pharmacology (12.2)]:  
•  with congenital long QT prolongation.  
•  with uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia.  
•  on anti -arrhythmic therapy or other substances that are known to lead to QT 
prolongation.  
•  with hypokalemia and/or hypomagnesemia.  
  A baseline ECG will be done at screening  and at hours 1, 1.[ADDRESS_770215] Elevations  
In the Phase III trial, 5% of patients had an ALT or AST level greater than 3 times the 
upper limit of normal (ULN). In the entire clinical development program of pasireotide, 
there were 4 cases of concurrent elevations in ALT (alanine aminotransferase) greater than [ADDRESS_770216]: one patient with Cushing’s disease and three healthy volunteers [see Adverse Reactions (6)]. In these cases, total bilirubin elevations were seen either concomitantly or preceding  the transaminase elevation.  
 Monitoring of liver tests should be done at baseline and weekly starting day 0 through 
transplant day  +100. If ALT is normal at baseline and elevations of ALT of 3- [ADDRESS_770217]. Tests should be done in a laboratory that can provide same- day results. If the values are confirmed or rising, interrupt p asireotide  treatment 
09/20 /[ADDRESS_770218] in case of normal baselines. If resolution of abnormalities to normal or near normal occurs, resuming treatment with p asireotide may be done cautiously, with close observation, and only if 
some other likely cause has been found.    See section 11.4 for dosing modification 
guidelines . 
 
8.7.5  Cholelithiasis  
Cholelithiasis has been frequently reported in clinical studies with p asireotide  [see 
Adverse Reactions (6)]. For this reason, a gallbladder ultrasound will be performed at 
baseline (within 30 days prior to starting pasireotide)  and between transplant days +4 
through +[ADDRESS_770219] day of pasireotide dosing.  
 
8.7.6  Monitoring for Deficiency of Pi[INVESTIGATOR_585648] p asireotide mimics that of somatostatin, inhibition of 
pi[INVESTIGATOR_56356], other than ACTH, may occur. Monitoring of pi[INVESTIGATOR_301] (e.g., 
TSH/free T4, GH/IGF -1) should occur at screening  and at  transplant  day +14. . Patients 
who have undergone transsphenoidal surgery and pi[INVESTIGATOR_585649].  
9 PATIENT ELIGIBILITY  
 
9.1 Inclusion Criteria  
• 18 years of age or older  at the time of study enrollment.  
• H istologically confirmed diagnosis for which an allogeneic transplant is utilized. 
• Plan to receive an allogeneic transplant from a 4 -6/[ADDRESS_770220] 
blood graft, or a 7- 8/8 HLA -matched sibling or unrelated donor (High resolution 
HLA-A, B, C, DRB1).  
• Meet standard criteria as defined by [CONTACT_436161] a myeloablative allogeneic stem cell transplantation, with myeloablative defined as using conditioning regimens containing:  
o TBI ≥ 1200 cGy, or  
o Busulfan ≥ 12.8mg/kg  
• Patient must have given written informed consent according to FDA guidelines.  
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures . 
  9.2 Exclusion Criteria  
• Female patients who are pregnant or lactating, or are of childbearing potential  
(FCBP, defined as all women physiologically capable of becoming pregnant) and 
not practicing an effect ive method of contraception/birth control  
•  FCBP  must have a current negative serum pregnancy test  prior to 
transplant per institutional practice. 
• Use of an investigational drug within 1 month prior to dosing .  
09/20 /2017 Page 23  of 61   • Concurrent enrollment on other clinical research studies that contain an 
interventional therapy is not permitted while subjects are receiving pasireotide or within 5 half -lives of finishing pasireotide. However, subjects may concurrently 
enroll in non- interventional studies (e.g. biobanking, mobile health tracking).  
• A ctive CNS disease  (related to primary malignancy)  at the time of enrollment.  
• Patients with existing grade 2 toxicities, except as approved by [CONTACT_093].  
• Any of the following diseases or conditions:  
• Cardiac:  
 History of unexplained syncope or family history of idiopathic 
sudden death.  
 Sustained or clinically significant cardiac arrhythmias . 
 Risk factors for Torsades de Pointes such as : 
• Uncontrolled hypokalemia  
• Uncontrolled hypomagnesemia or hypermagnesemia  
• C ardiac failure  ([LOCATION_001] Heart Association Class II or 
higher)  
• C linically significant/symptomatic bradycardia (HR<50) , or 
high-grade AV block . 
• K nown diagnosis of QT prolongation (QTc ≥470)  or family 
history of long QT syndrom e 
• Concomitant disease(s) that could prolong Q T such as 
autonomic neuropathy (caused by [CONTACT_37110], or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure . 
• Concomitant medications known to prolong the QT interval  
during the same time as pasireotide is to be administered (unless approved by [CONTACT_976] [INVESTIGATOR_585650] <470; standard transplant medications that are known to prolong the QT (e.g. azoles, ondansetron, etc.) are permitted but caution is advised and patients should be closely monitored) . 
• Endocrine:  
 Uncontrolled diabetes at the t ime of cytoreduction.  All patients with 
diabetes must be optimized on their diabetes regimen prior to 
initiating pasireotide. 
• If a patient is diabetic: u ncontrolled diabetes as defined by 
[CONTACT_13505]1c > 8%* despi[INVESTIGATOR_321778]   
 Patients who are not biochemically euthyroid. Patients with known history of hypothyroidism are eligible if they are on adequate and stable replacement thyroid hormone therapy for at least 3 months.  
 Known diagnosis of hypocortisolism  
 Known diagnosis of pi[INVESTIGATOR_269639].  
 Known hypersensitivity to somatostatin analogs or any component 
of the pasireotide LAR or s.c. formulations .  
• Infectious:  
 Uncontrolled (not being treated)  infections at the time of 
cytoreduction. 
09/20 /2017 Page 24  of 61    A positive HIV test result (ELISA and Western blot)  or histor y of 
known HIV. An HIV test will not be required; however, previous 
medical history will be reviewed.  
• Gastrointestinal:  
 Moderately impaired hepatic function (Child- Pugh B) or  severe 
hepatic impairment (Child- Pugh C )  
 Known gallbladder or bile duct disease, symptomatic cholelithiasis, acute or chronic pancreatitis . 
 Known malabsorption syndrome, short bowel or chologenic 
diarrhea not controlled by [CONTACT_585678].  
• Hematologic:  
 Abnormal coagulation (PT or aPTT >30% above normal limits) . 
 Continuous anticoagulation therapy. Patients who were on 
anticoagulant therapy must complete a washout period of at least [ADDRESS_770221] confirmed normal coagulation parameters before study inclusion. 
• Miscellaneous:  
 Major surgery/surgical therapy for any cause within [ADDRESS_770222] a good clinical condition before entering the study.  
 Any co -morbid condition which, in the view of the Principal 
Investigator, renders the patient at high risk from treatment complications.  
• Patients with a history of non- compliance to medical regimens or who are 
considered potentially unreliable or will not be able to complete the entire study . 
 
9.[ADDRESS_770223] consented to this study will be assigned a unique study ID consisting of the abbreviation  of the site nam e followed by [CONTACT_585679]- digit numbering.  
 In the case of screen failures, study IDs will not be reassigned and patient numbering will continue with the next consecutive number at that site.  For example:  
 
Duke  [LOCATION_005] General  
D[LOCATION_006] -001 MGH -001 
D[LOCATION_006] -002 MGH -002 
D[LOCATION_006] -003 MGH -003 
  10 MATERIAL AND DATA  
  This protocol will require  collection o f basic demographic data, data on GVHD, and all 
toxicity data (related and unrelated to pasireotide).    
 Study -specific data to be collected following initiation of study pasireotide :  
09/20 /2017 Page 25  of 61   • Basic demographic information to be collected at screening.  
• Data  will be recorded regarding the subject’s conditioning regimen, GVHD 
prophylaxis, and any GVHD treatment received. 
• Routine labs and LFTs will be collected at screening, baseline, and transplant 
Days 0, +7, +14, continuing weekly through Day +100. 
• Serum hCG pregnancy test will be performed at screening.  
• Fasting plasma glucose or HbA1c, TSH, Free T4, Growth Hormone, and IGF -1 to 
be assessed at screening and on transplant Day +14.  
• Plasma citrulline  samples will be collected  at baseline and on transplant days   0, 
+7, and + 14. 
• Fecal calprotectin samples will be collected at baseline and on transplant days  0, 
+7, and + 14.  A +/ - 1 day window is allowed for the collection of fecal samples.  
• 12-Lead ECGs will be completed at screening,  and at  [ADDRESS_770224] dose of pasireotide .. 
• A gallbladder ultrasound will be completed at baseline (acceptable to perform within 30 days prior to pasireotide initiation) and transplant days +4 through +6. 
• Toxicity assessments will be completed at baseline, daily while on pasireotide 
and recorded at transplant days +7, +14, +21, +28 and + 35.  The maximum 
grade of each toxicity occurring in the preceding period will be recorded at each assessment point.   
• Starting at Transplant Day 0, acute graft -versus- host disease is to be graded 
weekly through day + 100, and on Day +180, and +365 u sing the BMT CTN 
Manual of Procedures, Version 3 (BMT CTN, 2013)17.  The maximum grade of 
GVHD that occurred during each assessment period should be reported.  
• Chronic graft -versus -host disease is to be graded at Transplant Day +100, +180, 
+270, and +365 using the 2014 NIH Consensus Criteria (Jagasia et. Al., 2014)18.  
The maximum grade of GVHD that occurred during each assessment period should be reported.  
•  O verall and disease- free survival, along with cause of death (if applicable)  is to 
be assessed at transplant day  +100, +180, and +365.   
 Duke Only:  
• A subset of 10 patients will complete a video capsule endoscopy between 
Transplant Days +4 through +6. 
  
11 TREATMENT PLAN AND MODIFICATIONS  
  The plan would be an initial phase II study to measure efficacy , as well as toxicity , of 
pasireotide in decreasing grade 3- 4 GI toxicities through Transplant Day +30.  
   Study Phase:  
 
09/20 /2017 Page 26  of 61   The proposed study will be a phase II, non- randomized study. If the phase II study 
demonstrates improved efficacy, we would propose to move this to a phase III. Data 
collected from these patients would be significant to help inform the design and potential efficacy of this drug.  
 11.1  Study Design:   
The study design will be a non- randomized phase II. Forty p atients receiving an ablative 
preparatory regimen will receive p asireotide subcutaneous  (0.9 mg  Q12H .) one day 
prior to initiation of the preparatory regimen (at least 1 5 hours prior to initiation of 
conditioning) and continuing for four days following stem cell transplant not to exceed 
14 days  total dosing  of pasireotide (i.e. stop on Day +4 after transplant or Day 14 of 
pasireotide, whichever is sooner  - maximum of 28 doses ). Myeloablative preparatory 
regimens are defined as those including either TBI ≥ 1200 cGy or busulfan ≥ 12.8 mg/kg.  We will select matched controls  from existing patients who did not enroll on the 
pasireotide study  to minimize the time it takes to complete the trial.  
 The most common regimens combine TBI with cyclophosphamide (TBI/Cy) or busulfan with cyclophosphamide (Bu/Cy) (Appendix  E).  However, any regimen meeting the 
above definition of myeloablative preparatory regimen may be used . 
 The study will co llect data at screening, at baseline prior to initiation of the drug  (day of 
study drug start) , transplant day 0, day +7, day + 14  and weekly thereafter until day 
+100, and on day s +180, +270, and +365.. The total days on pasireotide therapy will be 
recorded as well as any SAE that is outside the expected for stem cell transplantation. We will also follow the incidence and severity  of acute and chronic GVHD.  
 11.2  Video Capsule Endoscopy  
At Duke only, a video capsule endoscopy will be performed in a subset of ten study 
patients  between transplant days +4 through +6. This substudy is descriptive in nature 
and only used to collect a source of preliminary data that may suggest further study.    Patients must agree to participate in this portion of the study and will be asked to sign a clinical consent for performance use of the video capsule endoscopy. Patients will be 
given detailed instructions to prepare for the procedure (Appendix B ). 
  
An in vestigator who is blinded to the group allocation of the patients/volunteers 
separately will review the images obtained from each of the capsule examinations.  
Images will be examined for evidence of the four following types of abnormalities: 
reddened/edema/villous blunting, erosion, ulcer and stenosis .  Each  of these categories 
will be score d from  0-3 and summed to obtain an overall index that will range from 0 
(normal study) to 12 (severely abnormal in all categories) . 
 A baseline video capsule endoscopy will not be performed, as at baseline  patients will not yet have begun myeloablative conditioning ( e.g., pasireotide starts Day -5 , 
myeloablative conditioning starts Day -4 ). Therefore, endoscopi[INVESTIGATOR_585651] (all scores = 0).  As a result, we do not think it is ethical to subject patients to 
09/20 /2017 Page 27  of 61   a video capsule endoscopy at baseline as we do not think there is any scientific 
benefit.  Furthermore, we do not propose to compare video capsule endoscopy at end of 
trial to baseline; rather, we propose to compare video capsule endoscopy at transplant Day 4-[ADDRESS_770225] these studies at baseline, Day 0, Day +7, and Day + 14. 
 11.[ADDRESS_770226] setting [ 13].   
 
• Citrulline Assay: Collect one 6.0ml Sodium Heparin (NaH – green top) tube at 
each timepoint. Sample should be labeled with patient’s study ID, sample type, and date and time of sample collection.  Process sample within 2 hours.  
o Thoroughly mix the blood by [CONTACT_99977] 8 to 10 times.  
o Centrifuge at approximat ely 2500 rpm for 10 minutes until serum is well 
separated.  
o Use pi[INVESTIGATOR_585652] 3 sterile 2ml cryovials.  
o Ensure that each cryovial is labeled with patient’s study ID, sample type, and date and time of sample collection; no PHI should be included.  
o Freeze at - 80°C until shipment.  
o Ship frozen on dry ice.  
 
11.3.2 Calprotectin assay  
Calprotectin has been described as another biomarker of GI injury.  During radiation-induced inflammation, leucocytes infiltrate the mucosa and increase the level of fecal calprotectin [ 15, 16].  Calprotectin will be measured with an ELISA kit (CALPRO, Oslo, 
Norway) in accordance with the manufacturer’s instructions.  
 
• Calprotectin Assay: Collect at least a 50 mg (walnut -sized)  stool sample into a 
sterile specimen container (with no additive) at each timepoint (+/ - 24 hours). 
Sample should be labeled with patient’s study ID, sample type, and date and 
time of sample collection. Refrigerate until processed. Process sample within 24 
hours as follows:  
o Stool should be mixed using a disposable sterile spatula (if solid) or dropper (if liquid) and transferred into cryovials using that same spatula or dropper . 
o Aliquot stool sample evenly into 9 sterile 2 -ml cryovials.  
o Ensure that each cryovial is labeled with patient’s study ID, sample type, and date and time of sample collection; no PHI should be i ncluded.  
09/20 /2017 Page 28  of 61   o Freeze at - 80°C until shipment.  
o Ship frozen on dry ice. 
 
Please ship all samples to the attention of:  
 
Chao Lab c/o Megan Baker  
  [ADDRESS_770227]  
Genome Sciences Research Building I, Rm 4022  
Durham, NC  [ZIP_CODE]  
 11.4  Dose Modifications and Treatment Interruptions /Discontinuation 
 If the patient  experiences toxicities requiring dose reduction of pasireotide, the reduced 
dose will be maintained for all subsequent doses unless further toxicities occur. No dose re-escalation is permitted.  
 If pasireotide dosing is held, the study calendar is not aff ected and all study visits will 
remain due at the originally scheduled time.  Pasireotide therapy should end by [CONTACT_585680] +4 or 14 days of treatment (28 total doses), whichever is sooner.  
 Pasireotide Dose Adjustment Schedule  
 
Dose Level 0 (Starting D ose) 0.9mg Q12H  
Dose Level -1 0.6mg Q12H  
Dose Level -2 0.3mg Q12H  
Dose Level -3 Discontinue  Pasireotide  
 If the patient experiences a toxicity ≥  Grade 3 (CTCAE v.4) suspected to be related to 
pasireotide , hold pasireotide until the toxicity resolves to ≤  Grade 3 and restart  
pasireotide  with a one level dose reduction according to the table above.  
 If the patient experiences a toxicity ≥  Grade 4 that is judged to be unrelated to 
pasireotide , hold pasireotide until the toxicity resolves to < Grade [ADDRESS_770228]  
 Hyperglycemia – should be managed per institutional practice [guidance for glucose 
management suggested in Appendix C]  
• For Glucose > 250 but < 500 mg/dL , treat according to institutional practice. 
Pasireotide dosing may continue at same dose.  
• For Glucose >500 mg/dL, hold pasireotide and treat according to institutional 
practice. Pasireotide may be restarted with a one level dose reduction when glucose has been reduced to < 500mg/dL.  
 Elevated LFTs  
09/20 /2017 Page 29  of 61   • If ALT, AST, or Alkaline Phosphatase is ≥  Grade 3, regardless of attribution, 
hold pasireotide. Pasireotide may be restarted with a one level dose reduction 
when toxicity has resolved to < Grade 3.  
  
In addition, if any of the following criteria are met, study drug may be discontinued at the  
discretion of the investigator : 
• Unacceptable toxicity that, in the judgment of the investigator, compromises the  
ability to c ontinue study -specific procedures or is considered to not be in the 
subject’s  best interest  
• Subject request to discontinue for any reason  
• Proven non- compliance with treatment or scheduled evaluation  
• Discontinuation of the study at the request a regulatory  agency, or  the governing 
institutional review board (IRB)  
11.[ADDRESS_770229] is to be withdrawn from study in the event of:  
• Disease relapse,  
• Subject never receives pasireotide,  
• Graft failure (withdrawal to occur at the time when new antineoplastic therapy or conditioning chemotherapy for a 2
nd transplant is initiated),  
• Transfer to Hospi[INVESTIGATOR_6125],  
• or other such events approved by [CONTACT_115158].  
  [ADDRESS_770230] an expected rate of events. While we realize 21CFR312.32 
(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32
) does 
not draw a distinction between suspected events related to the study drug and suspected events related to normal medical care (i.e. HSCT), because HSCT is  
associated with such a high rate of expected adverse events, we believe the distinction between "suspected- related to HSCT" and "suspected- related to study drug" is relevant, 
and prefer this terminology to "expected", "labeled", and "non- labeled" (though we retain 
the category of "unexpected" as suggested and per 21CFR312.32). We will specifically 
assess for unexpected adverse events as these patients are closely monitored on a daily basis.  
 Clinically significant adverse reactions associated with the admi nistration of p asireotide  
that appear in “Warnings” sections of this protocol include:  
 
• Hyperglycemia and Diabetes  
• Bradycardia and QT prolongation  
• Liver test elevations  
• Cholelithiasis  
• Pi[INVESTIGATOR_269639]  
09/20 /2017 Page 30  of 61   • Hypocortisolism  
 
The following toxicities  are anticipated following allogeneic stem cell  transplantation and 
will therefore not be reportable to the IRB unless they occur at a frequency that suggests association with the study drug . 
 12.1 Myelosuppression:   
Following donor stem cell engraftment, persistent pancytopenia is common following allogeneic stem cell transplantation.  Marrow aplasia may be incited by [CONTACT_585681].  
 
12.2 Gastrointestinal:   
Nausea and vomiting can be expected during the post -transplant period.  The most 
common cause for GI disturbance is drug -related or residual mucosal damage from the 
bone marrow preparative regimen. Mucositis and diarrhea may also occur and will be supported with standard measures.  
 12.[ADDRESS_770231] that optimal glucose control should be achieved before starting a patient on pasireotide.  
 12.4 Cardiac:   
High-dose chemotherapy can cause acute cardiotoxicity in doses used in this protocol 
(congestive heart failure, pericardial effusion, arrhythmias, EKG changes).  Rarely, these may prove to be lethal.  Pericardial effusions can also occur as an unusual manifestat ion of graft versus host disease.  
 A small number of cases of QT prolongation have been reported in some           participants in pasireotide clinical trials.  QT is one of the measurements taken during an ECG (heart tracing) and increase (prolongation) i n QT may lead to an irregular 
heartbeat which in rare instances can develop into a sudden, life- threatening condition. 
The majority of cases that were reported in the pasireotide clinical trials resolved or improved spontaneously without discontinuation of  the study drug. Though the risk is 
small, these findings may indicate a potential risk for an irregular heart rate associated with the treatment with pasireotide.  
 12.5 Pulmonary:   
Pulmonary toxicity from the preparative regimen has been described, and often presents as diffuse alveolar hemorrhage. Hemorrhage may also occur within the first 100 days following transplantation, although the inciting event is likely not the bone marrow preparative regimen.  Diffuse interstitial pneumonitis of unknown etiology (infectious, toxic, or multifactorial) is a well -described toxicity of intensive chemotherapy 
and TBI regimens and may prove lethal. TBI may also cause late pulmonary dysfunction.  
09/20 /2017 Page 31  of 61    
12.6 Hepatic:   
Tacrolimus  or other hepatoxic drugs may result in elevated levels of hepatic enzymes  
and may also cause elevations in bilirubin.  
 
12.7 Renal:   
Mild elevations of BUN and creatinine may be seen in patients treated with high dose chemotherapy and/or Tacrolimus.  These are  generally reversible.  Renal dysfunction, 
which is usually mild and reversible, may rarely be seen after TBI at the doses used in this protocol.  A syndrome of moderate renal insufficiency and hemolysis (Thrombotic -
thrombocytopenic purpura/hemolytic uremic syndrome) has been seen 5- [ADDRESS_770232]-bone marrow transplantation after intensive multi -agent conditioning +/ - TBI.  This 
also is usually reversible, but the long -term sequelae are not yet clear.  
 12.8 GVHD:   
Grade II- IV acute GVHD occurs in 20- 40% of patients receiving matched- sibling or 
partially matched allogeneic stem cell transplantation.  GV HD typi[INVESTIGATOR_585653], 
liver function test abnormalities and colitis. The severity of the acute GVHD is quite 
variable, however the severe cases can  be fatal.  Chronic GVHD occurs greater than 
100 days following stem cell transplantation and affects approximately 50% of recipi[INVESTIGATOR_840].  Chronic GVHD is manifested in the skin, liver, mucous membranes and less 
commonly in the lung and intestinal tract.  10 to 20% of those patients who develop chronic GVHD will ultimately die of complications stemming from this disease.  
 12.9 Neurologic:   
Posterior reversible encephalopathy syndrome (PRES)  may occur as a consequence of 
the total body irradiation.      12.10 Miscellaneous : 
• Transfusion reactions  
• Glucose intolerance due to multiple medications ( e.g. calcineurin inhibitors and 
glucocorticoids  
• Late effects of transplant regimens including: cataracts, infertility, growth 
impairment, hypothyroidism, and dental cari es. 
• Headache, insomnia, psychosis, mood changes, disorientation, seizures from 
metabolic imbalance.  
• Well-characterized drug reactions - allergic manifestations, "red man" syndrome. 
well-characterized drug side effects from drugs used routinely in transplant 
recipi[INVESTIGATOR_840] (e.g.; preparative regimen chemotherapy, immunosuppressive drugs, antimicrobials)  
• Common side effects of antiemetics, analgesics, anti -inflammatory agent and 
known complications of steroid therapy.  
• Complications from intravenous catheters, thrombotic occlusion, infection, local 
reactions, cardiac arrhythmia. Post-transplant microangiopathy.  
  
09/20 /2017 Page 32  of 61   13 DATA MANAGEMENT AND DATA SAFETY MONITORING  
 
 13.1 Data Management  
 
13.1.1  Electronic Case Report Forms (eCRFs)  
This study will utilize eCRFs in a REDCap database for data reporting. REDCap is a 
software tool that does not require client local software and can be accessed from anywhere on the Internet and is secured on a Duke Health Technology Services (DHTS) server. This database will be developed and maintenance performed with support of the School of Medicine (SOM) Duke Office of Clinical Research (DOCR). SOM’s DOCR has partnered with the School of Medicine (SOM) to implement REDCap (developed by [CONTACT_29392]’s CTSA  and currently used and supported by [CONTACT_726] 1600 
consortium partners. REDCap provides: 1) a stream -lined process for rapi[INVESTIGATOR_188930] a 
database; 2) an intuitive interface for collecting data (with data validation and audit trail); 3) automated export procedures for seamless data downloads to common statistical packages (SAS, SPSS, etc.); 4) branching logic, file uploading, and calculated fields; and 5) a quick and easy protocol set -up.  
 REDCap accounts are stored within the DTMI LDAP server hosted by [CONTACT_585682] (OIT). Authentication occurs via the OIT implementation of Kerberos. All connections to the system, both external and internal, occur over encrypted channels. Access to components of the system is role- based and can only be 
granted by [CONTACT_220398]. All collected information is stored on a database server hosted by [CONTACT_423080] (DHTS). The database server resides behind the DHTS internal firewall and access to the server is controlle d 
via firewall rules. All collected data are backed up daily, both on the local server and by [CONTACT_438668]. The Office of Research Informatics -App 
Engineering -DHTS (ORI) via ServiceNow (919 668- 7286) is responsible for managing 
the server for REDCap. Duke Office of Clinical Research (Ceci Chamorro 919- 668-
9262) is responsible for managing the database platform for REDCap. At the time of this submission, REDCap is on version 6.5.15.
[ADDRESS_770233] original source documents.  Source documentation for study data points may be 
redacted, labeled with the subjects ’ study ID, and sent to the coordinating site via email 
or fax.  This source documentation will be filed in individual subject study binder s for 
verification at monitoring visits and study audits.   
  Alternatively, source documentation may be verified remotely through direct access to the electronic medical record via secure methods approved by [CONTACT_585683] [INVESTIGATOR_7966].  
09/20 /2017 Page 33  of 61    
13.1.3 Study Clo sure 
Following completion of the studies, the PI [INVESTIGATOR_346027]:  
 
• Data clarification and/or resolution  
• Accounting, reconciliation, and destruction/return of used and unused study drugs  
• Review of site study records  for completeness  
• Shipment of all remaining laboratory samples to the designated laboratories  
 13.[ADDRESS_770234] is enrolled, followed by [CONTACT_12636] 1- 3 subjects until the study is closed to enrollment and 
subjects are no longer receiving study interventions that are more than minimal risk.  
 The Safety Oversight Committee (SOC) wi ll perform annual reviews on findings from 
the DCI Monitoring Team visit and additional safety and toxicity data submitted by [CONTACT_079].  
 Additional monitoring may be prompted by [CONTACT_12637], unexpected frequency of serious and/or unexpected toxicities, or other concerns and may be initiated upon request of DUHS and DCI leadership, the CPC, the Safety Oversight Committee (SOC), the sponsor, the Principal Investigator, the Duke Clinical Trials Quality Assurance (CTQA) off ice or the IRB.  All study documents must be made 
available upon request to the DCI Monitoring Team and other authorized regulatory authorities, which may include but is not limited to the FDA.  Every reasonable effort will be made to maintain confidential ity during study monitoring.  
   14 SAFETY AND STUDY DATA MONITORING  
  14.1  Safety  
 
14.1.1 Adverse Event Reporting.    
The investigator is required by [CONTACT_585684]  (AEs) that 
occur through the duration of the study according to the appropriate procedures listed 
below.  The investigator is required to notify the FDA, and Duke University Health 
System (DUHS) Institutional Review Board (IRB) Office if an event is serious, unexpected, and related or possibly related to the drug. 
09/20 /[ADDRESS_770235]  all grades 2 -4 adverse events  (excluding lab values)  from the time of 
consent through [ADDRESS_770236] dose of pasireotide.  It will be noted if the event 
arose from a preexisting or grade 1 toxicity.  
•         Each event needs to be categorized as one of the following:  
o   Expected – Related to transplant (sections 12.1- 12.10)  
o   Expected – Related to Pasireotide ( section 12.0) 
o   Unexpected – Related to Transplant  
o   Unexpected – Related to Pasireotide  
 
 All "life -threatening" and "serious adverse events" will be reported regardless of 
suspi[INVESTIGATOR_585654]. In addition, we plan to report  "suspected -related to study drug" 
and "unexpected" events.  We do not propose to report adverse events that 
are "suspected- related to HSCT" that are not "life- threatening" or "serious adverse 
events" as nearly 100% of patients undergoing HSCT will experience adverse events that are "suspect ed-related to HSCT" (e.g. historical rate of GI toxicity of myeloablative 
HSCT itself  is 90%, not to mention myelosuppression (100% of patients) and other 
common adverse events related to HSCT).  
 Definitions:  An adverse event is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.  
 A serious adverse event  (SAE) : an adverse event  or suspected adverse reaction is 
considered "serious" if, in the view of either the investigator, it results in any  of the 
following outcomes : 
• Death  
• A life-threatening  adverse event in the view of the investigator its occurrence 
places the patient at immediate risk of death  
• Inpatient hospi[INVESTIGATOR_1081]  
• A persistent or significant incapacity  or substantial disruption of the ability to 
conduct normal life functions  
• A congenital anomaly/birth defect  
 Important medical events that may not result in death, be life- threatening, or require 
hospi[INVESTIGATOR_708],  based upon appropriate medical 
judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed above. 
 Suspected adverse reaction means any adverse event for which there is a reasonable poss ibility that the drug caused the adverse event. For the purposes of IND safety 
reporting, "reasonable possibility" means there is evidence to suggest a causal relationship between the drug and the adverse event. Suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.  
 
09/20 /2017 Page 35  of 61   Unexpected adverse event or  unexpec ted suspected adverse reaction. An adverse 
event or suspected adverse reaction is considered "unexpected" if it is not listed in the 
investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application.  
 Any SAE will be reported to Duke, [COMPANY_001], and t he FDA  as soon as possible, but in no 
case later than 7 calendar days after receipt of the information .  Each notification to 
FDA will be transmitted to the review division in the Center for Drug Evaluation and 
Research or in the Center for Biologics Evaluation and Research that has responsibility for review of the IND  
 This study will utilize the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0 to determine the severity of the reaction for adverse event reporting. Any 
reaction that is reportable (serious, unexpected and related/possibly related to the study) must be reported using the FDA #3500 MedWatch form  and the [COMPANY_001] SAE 
coversheets (Appendix H).   All AEs reported will be recorded on an electronic AE Case 
Report Form (CRF).    
 
14.1.2 SAE Reporting 
The principal investigator [INVESTIGATOR_36891], IRB, and [COMPANY_001] Pharmaceuticals Drug Safety and Epi[INVESTIGATOR_066] (DS&E).  
 All events reported to the FDA by [CONTACT_109] 3500A (MedWatch Form)  and the [COMPANY_001] SAE coversheets  (Appendix H) .  
 
To ensure patient safety, every SAE, regardless of suspected causality, occurring  after 
the patient has provided informed consent and until at least [ADDRESS_770237] be reported to Duke ( Fax: 919 -668-1091) and [COMPANY_001] 
within 24 hours of learning of its occurrence (F ax: [PHONE_5204])  using the 
coversheets found in Appendix H . This includes serious, related, labeled (expected) and 
serious, related, unlabeled (unexpected) adverse experiences. All deaths during 
treatment or within [ADDRESS_770238] be provided.  
 
09/20 /[ADDRESS_770239] be kept within 
the Trial Master File at the study site.  
 Follow -up information is sent to the same fax number as the original SAE Report Form 
was sent, using a new fax cover sheet, stating that this is a follow -up to the previously 
reported SAE, and giving the date of the original report. Each re- occurrence, 
complicatio n, or progression of the original event should be reported as a follow -up to 
that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was broken or not (if applicable), and whether the patient continued or withdrew from study participation.  
 If the SAE is not previously documented in the SOM230 Investigator Brochure or Package Insert (new occurrence) and is thought to be related to the Novarti s study 
drug, a DS&E associate may urgently require further information from the investigator for Health Authority reporting. [COMPANY_001] may need to issue an Investigator Notification (IN), to inform all investigators involved in any study with the same drug  that this SAE 
has been reported.  Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will 
be collected and reported to the competent authorities and relevant ethics committees in accordance with Directive 2001/20/EC or as per national regulatory requirements in participating countries.  
 For Comparator Drugs/Secondary Suspects (Concomitant Medications), all serious adverse experiences will be forwarded to the comparator drug company by [CONTACT_093].  
 
14.1. [ADDRESS_770240] be reported to Duke and [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. The newborn will be followed for at least 12 months.  
 Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_585685][INVESTIGATOR_31908] (DS&E). Pregnancy follow -up should be recorded on the same form and 
should include an assessment of the possible relationship to the study treatment and 
any pregnancy outcome. Any SAE experienced during pregnancy must be reported on the SAE Report Form.  
 
09/20 /2017 Page 37  of 61   14.2 Data Monitoring:  
This clinical research study will be monitored both internally by [CONTACT_978] [INVESTIGATOR_585655]’s Protocol Review and Monitoring system in accord with their NCI - approved “Institutional Protocol Monitoring  Procedures 
and Guidelines for NIH -Sponsored Research Involving Hum an Subjects.”  
 In terms of internal review,  the PI [INVESTIGATOR_79761]- PI [INVESTIGATOR_585656]. Appropriate reporting to the Duke University Medical Center IRB will be made.  If an  unexpected frequency of grade III or IV events occur, depending on their 
nature, action appropriate to the nature and frequency of these adverse events will be taken.  This may  require a protocol amendment, or potential closure of the study.  The 
severity of adverse events will be classified according to t he NCI CTC.   
 The DCI Monitoring Team will conduct monitoring visits to ensure subject safety and to ensure that the protocol is conducted, recorded, and reported in accordance with the protocol, standard operating procedures, good clinical practice, and applicable regulatory requirements.   As specified in the DCI Data and Safety Monitoring Plan, the 
DCI Monitoring Team will conduct routine monitoring after the third subject is enrolled, followed by [CONTACT_12636] 1 – 3 subjects until the study is cl osed to enrollment 
and subjects are no longer receiving study interventions that are more than minimal risk.    The DCI Safety Oversight Committee (SOC) will perform annual reviews on findings from the DCI Monitoring Team visit and additional safety and toxicity data submitted by [CONTACT_079].  
 Additional monitoring may be prompted by [CONTACT_12637], unexpected frequency of serious and/or unexpected toxicities, or other concerns and may be initiated upon request of DUHS and DCI leadership, the CPC, the Safety Oversight Committee (SOC), the Duke  University Office of Audit, Risk, and Compliance- Human 
Subjects Research Compliance Office, the sponsor, the Principal Investigator, or the IRB.  All study documents must be made available upon request to the DCI Monitoring 
Team and other authorized regulatory authorities, which may include but is not limited to the National Institute of Health, National Cancer Institute, and the FDA.   Every 
reasonable effort will be made to maintain confidentiality during study monitoring.  
 The Duke University Office of Audit, Risk, and Compliance – Human Subjects Research 
Compliance (OARC HSRC) office may conduct confidential audits to evaluate 
compliance with the protocol and the principles of GCP. The PI [INVESTIGATOR_585657](s) direct access to all relevant documents and to allocate his/her time and the time of the study team to the OARC HSRC auditor(s) in order to discuss 
findings and any relevant issues.  
  15 STATISTICAL CONSIDERATIONS  
 
09/20 /2017 Page 38  of 61    
15.1  Objectives  
 
15.1.1  Primary Objective:   
To evaluate the efficacy and safety of pasireotide in mitigating GI toxicity f rom the 
preparatory regimens of  allogeneic stem cell transplantation compared to historical 
controls .   
 
The control group will be selected from about 400 existing patients who did  not enroll on 
this study. This group will be matched based on age, disease, GVHD prophylaxis, preparatory regimen (TBI or busulfan) , graft source, and number of prior therapi[INVESTIGATOR_014].   
 Efficacy will be assessed as the incidence of all Grade III -IV gastrointestinal toxicities 
occurring from the baseline visit through transplant  day +30. Toxicities will be graded 
according to CTCAE v. 4.0 and labeled using CTCAE criteria found under the heading of “Gastrointestinal disorders”.  This will include symptoms of nausea, vomiting, diarrhea, abdominal pain, distention, mucositis, and the like.  It will be noted if the toxicity 
arose from a preexisting  or grade 1 toxicity.  
 
15.1.2 Secondary Objectives:   
To evaluate the efficacy of pasireotide in reducing the incidence and severity of acute 
GVHD at [ADDRESS_770241] -transplant to historical controls.   
 15.2  Exploratory Objectives:  
To evaluate plasma citrulline and fecal calprotectin levels as biomarkers of GI tract health and function in SCT patients and the correlation between these biomarkers and GI toxicity.   The control population would consist of bone marrow transplant patients, 
being seen concurrently and who also consented to participat e in Pro00006268.  
 To evaluate GI toxicity assessment  by [CONTACT_585670].   We will enroll 10 
subjects who take pasireotide and 5 controls who do not receive pasireotide.   
 15.3  Endpoints:   
 
15.3.[ADDRESS_770242] patients who are treated with pasireotide.  
09/20 /[ADDRESS_770243] for the hy pothesis H0: p0≤p1 versus H1: 
p0>p01, where p0 and p1 are the rates of GI toxicity for SCT patients who don’t take 
pasireotide and who take pasireotide, respectively. Historical data show that the rate of GI toxicity without the drug is about 90%, and w e expect that the GI toxicity rate in 
patients who receive pasireotide will decrease to about 50%. With this number of patients, the power of the test is close about 0.99  with a type I error rate 0.05 under our 
expected rates of GI toxicity. We can still achi eve 80% power under a very conservative 
estimate of GI toxicity rate for those who take drug of [ADDRESS_770244] for the hypothesis H0: q0=q1 versus H1: q0>q1 using the Chi -
square test, where q1 and q0 are the rates of GVHD in patients with and without 
pasireotide respectively.  
 We will compare GVHD incidence rates between treatment group versus historic al 
control group  using survival type regression modeling that takes competing risks into 
account. We will examine cause -specific Cox proportional hazards models as well as 
the proportional subdistribution hazard regression model developed by [CONTACT_585686].  
While the primary treatment comparison will be unadjusted, adjustment for covariates to explore the impact of various risk factors will also be performed.  
 Survival outcomes will be analyzed in a similar fashion to GVHD, as described above.  
 
15.3.3 Exploratory Endpoints   
As exploratory endpoints, citrulline and fecal calprotectin levels will be measured at 
baseline and transplant day 0, + 7, and + [ADDRESS_770245]  measured biomarker  level 
and the incidence of  GI toxicity.   
 
Video Capsule  
The means of mucositis in the video endoscopy group and the control group will be compared using the Student’s t test.  
15.4  Stoppi[INVESTIGATOR_585658] 6 -month treatment related mortality (TRM) in two stages. At DUMC, the 
TRM rate has been 0.[ADDRESS_770246] care (consistent with rates in the literature of 16-
30%). We will consider a rate of .35 or higher to be unacceptable.   We will use the 
following sequential rules to determine early stoppi[INVESTIGATOR_585659].  
Stage  Number of patients accrued  Stop trial if 6 -month TRM 
≥ 
1 15 6 
2 30 11 
09/20 /[ADDRESS_770247] probability of 0.13 of stoppi[INVESTIGATOR_585660] 0.20 and a probability of 0.86 of stoppi[INVESTIGATOR_585661] 0.35.  
    
09/20 /[ADDRESS_770248] and radiation casualties . Hematology Am 
Soc Hematol Educ Program, 2003: p. 473- 96. 
2. Hauer -Jensen, M., et al., Radiation damage to the gastrointestinal tract: 
mechanisms, diagnosis, and management.  Curr Opin Support Palliat Care, 2007. 
1(1): p. 23- 9. 
3. Nejdfors, P., et al., Intestinal permeability in humans is increased after radiation 
therapy.  Dis Colon Rectum, 2000. 43(11): p. 1582- 1587; discussion 1587- 8. 
4. Morgenstern, L. and N. Hiatt, Injurious effect of pancreatic secretions on postradiation enteropathy.  Gastroenterology, 1967. 53 (6): p. 923 -9. 
5. Hauer Jensen, M., et al., Influence of pancreatic secretion on late radiation enteropathy in the rat.  Acta Radiol Oncol, 1985. 24 (6): p. 555- 60. 
6. Morgenstern, L., et al., Prolongation of survival in lethally irradiated dogs by 
[CONTACT_585687].  Arch Surg, 1970. 101(5): p. 586- 9. 
7. Shinozaki, H., et al., Effect of somatostatin on pancreatic enzyme secretion.  
Gastroenterol Jpn, 1988. 23(6): p. 673- 9. 
8. Williams, S.T., et al., Effect of octreotide acetate on pancreatic  exocrine function.  
Am J Surg, 1989. 157 (5): p. 459- 62. 
9. Wang, J., et al., The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury.  Int J Radiat Oncol Biol Phys, 1999. 
45(5): p. 1289- 96. 
10. Yavuz, M.N., et al., The efficacy of octreotide in the therapy of acute radiation-
induced diarrhea: a randomized controlled study.  Int J Radiat Oncol Biol Phys, 
2002. 54(1): p. 195 -202. 
11. Ma, P., et al., Pharmacokinetic -pharmacodynamic comparison of a novel 
multilig and somatostatin analog, SOM230, with octreotide in patients with 
acromegaly.  Clin Pharmacol Ther, 2005. 78(1): p. 69- 80. 
12. Fu, Q., et al., The somatostatin analog SOM230 (pasireotide) ameliorates injury of the intestinal mucosa and increases survival af ter total -body irradiation by 
[CONTACT_585688].  Radiat Res, 2009. 171(6): p. 698 -707. 
13. Lutgens, L.C., et al., Monitoring myeloablative therapy -induced small bowel 
toxicity by [CONTACT_585689]: a comparison with sugar permeability tests.  Cancer, 2005. 103 (1): p. 191 -9. 
14. Gupta, P.K., et al., Development of high- throughput HILIC -MS/MS methodology 
for plasma citrulline determination in multiple species.  Analytical Methods, 2011. 
3(8): p. 1759- 1768.  
15. Hille, A., et a l., A prospective study of faecal calprotectin and lactoferrin in the 
monitoring of acute radiation proctitis in prostate cancer treatment.  Scand J 
Gastroenterol, 2008. 43(1): p. 52- 8. 
16. Larsen, A., et al., Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pi[INVESTIGATOR_585662].  Scand J Gastroenterol, 
2004. 39(11): p. 1113- 8. 
17. Blood and Marrow Transplant Clinical Trials Network, Technical Manual of Procedures . 2013. 3 : p. 6-7. 
09/20 /[ADDRESS_770249] Disease: I. The 2014 
Diagnosis and Staging Working Group report.  Biology of Blood and Marrow 
Transplant. 2015 Mar;  21(3): p389- 401.e1. doi:10.1016/j.bbmt.2014.12.001. 
Epub 2014 Dec 18.  
19. P.A. Harris, R. Thielke, R. Taylor, J. Payne, N. Gonzalez, J.G. Conde. Research 
Electronic Data Capture (REDCap) - A metadata- driven methodology and 
workflow process for providing translational research informatics support. Journal of Biomedical Informatics, 2008 (doi:10.1016/j.jbi.2008.08.010).  
   
09/20 /2017 Page 43  of 61   APPENDIX A: Study Calendar  for Special Studies  
 
Assessments solely related to the stem cell transplant will be done per institutional standards and are not included below.  
Studies 
specific for 
pasireotide   Screening10 Baseline/Start 
of Study Drug (day before 
conditioning)  Day 
06 Day 
+4 Day 
+7 Day 
+14 Weekly  
through Day 
+100  Day 
+30 
+/-7 
days  Day 
+60 
+/-7 
days  Day 
+100  
+/-14 
days  Day 
+180  
+/-14 
days  Day 
+270  
+/-14 
days  Day 
+365  
+/-[ADDRESS_770250] 
for FCBP  x             
Fasting plasma 
glucose or 
HbA1c  x     x        
Thyroid function 
tests: TSH/free 
T4, GH/IGF -1 x     x        
Gallbladder 
ultrasound   X8  x7          
Citrulline assay 
[12.3.1]   x x  x x        
Calprotectin 
assay [12.3.2]9  x x  x x        
Video Capsule 
Endoscopy 
[12.2]2    x          
Toxicity 
Assessments   x x  x X12        
09/20 /[ADDRESS_770251] in case of normal baselines.  
2 For subset of 10 subjects; only performed at Duke site. To be performed between transplant Day +4 and +6. 
3 LFTs will occur at baseline and weekly starting Day 0 through day + 100. 
4 CBC, Chemistry profile, PT/PT T, INR.  At baseline/start of study drug visit, labs are to be performed prior to first dose of pasireotide. 
[ADDRESS_770252] infusion of Pasireotide. 
6 Day 0 = the day of transplant. 
7 Gallbladder ultrasound to be completed between Transplant Day +4 and  +6 
8 To be performed within 30 days prior to start of pasireotide. 
9 Baseline calprotectin sample to be collected within 72 hours prior to start of pasireotide. All other calprotectin samples may be collected +/- 1 
day from expected assessment day.  
10 All screening assessments should be completed within 30 days prior to the start of pasireotide.  
11 Medications used for GVHD prophylaxis and all information regarding any GVHD treatment received during each study period will be recorded 
at each time point.   
12 Toxicity assessments to be completed at baseline, daily while on pasireotide, and then weekly through Transplant Day +35.  Maximum grade of 
each toxicity to be recorded at Baseline, Days 0, +7, +14, +21, +28, and +35.  Acute GVHD 
Assessments    x  x x x   x x  x 
Chronic GVHD 
assessments           x x  x 
Survival 
Analysis           x x  x 
09/20 /2017 Page 45  of 61   APPENDIX  B: CAPSULE ENDOSCOPY PREPARATION INSTRUCTIONS  
 
Your doctor has ordered a Video Capsule Endoscopy to evaluate your small intestines for conditions such as ulcers and bleeding. This procedure involves swallowing a capsule the size of a large vitamin pi[INVESTIGATOR_4382]. The capsule will pass through your small intestines taking pi[INVESTIGATOR_499]. The pi[INVESTIGATOR_585663] a small computer which you will wear on a belt around your waist. The test lasts [ADDRESS_770253] and go about your daily activities. At the end of that time, you will be asked to return the recording computer to the Gastroenterology (GI) Clinic, where the images will be downloaded for analysis. The video capsule is disposable and will usually pass naturally in your bowel movement within 24- [ADDRESS_770254] you with this. Call the GI Scheduling Hub 
at 919- 684-6437 if you need to reschedule your appointment or for any other questions.  
 Three (3) Days Before the Procedure : stop taking iron supplements  
 One (1) Day Before The Procedure:  
Stop taking antacids ( Tums, Rolaids), Pepto- Bismol, or Carafate, which coats the 
camera lens.  
AM :    You may eat a regular breakfast.  
11am:  After breakfast, CONSUME ONLY CLEAR LIQUIDS for the remainder of the day and evening. No more solid food.  Avoid anything that is colored red or purple.    See below for list of clear liquids.  
 7pm:   TAKE ONE DOSE (17 grams) OF MIRALAX o ver-the-counter laxative, mixed in 
water. (**Note: It is NOT necessary to move your bowels after this dose!)  
 12 Midnight :  DO NOT  EAT OR DRINK ANYTHING ELSE .  If you have any medications due, you may take them with sips of water.  
 Day of the Procedure:  
6am :   You may take your morning medications with small sips of water.  Do not take anything further by [CONTACT_1966].  
 o Diabetics:   check blood sugar.  Alter diabetic medications as discussed with GI Resource Nurse  
 Wear loose, comfortable [ADDRESS_770255] or abdomen.  
 
09/20 /2017 Page 46  of 61   8 - 9am : Arrive at assigned (GI) Clinic.  Location and time will be specified on your 
appointment letter. After meeting with the nurse and doctor, the recording computer will 
be attached to you with a belt and suspenders.  You will then swallow the capsule with a glass of water.  
 Once the capsule is swallowed, specific instructions on diet and care of recording equipme nt will be given to you.  A general guideline to the diet is as follows:  
0-2 hours after swallowing capsule:        Do not eat or drink.  
2 hours after swallowing capsule:           Clear liquids and medications.  
4 hours after swallowing capsule:           Light snacks.  
6 hours after swallowing capsule:           Regular diet.  
 The Capsule Endoscopy will last [ADDRESS_770256], and go about your daily activities (with some exceptions).  
 4 - 5pm : Return the equipment to the G I Clinic.  Resume regular diet and activities.  
 Clear Liquid Diet List :       (avoid anything that is colored Red or Purple)  
Beverages:  Soft Drinks ± orange, ginger ale, cola, Sprite, 7- Up, Gatorade G/G2, Kool -
Aid, Strained fruit juices without pulp ± apple, white grape, orange, lemonade, Water, tea, coffee (no milk or non- dairy creamer)  
 Soups:  Low-sodium chicken or beef bouillon/broth (broth may be strained off 
regular soup)  
 Desserts: Jell-O (lemon, lime, or orange; no fruit or toppi[INVESTIGATOR_14839]), Popsicles (no sherbet 
or fruit bars)  
  
09/20 /2017 Page 47  of 61   APPENDIX C: Guidance for hyperglycemia management  
 
Hyperglycemia is known to be associated with the treatment with somatostatin analogues (SSA).  Clinical studies of pasireotide in healthy volunteers and in patients with Cushing’s disease, acromegaly or carcinoid syndrome have reported transient, 
asymptomatic increases in fasting and postprandial glucose levels.   
 [COMPANY_001] has conducted 2 clinical studies ( [SOM230B2216]  and [SOM230B2124] ) to 
further understand the mechani sm of pasireotide- induced hyperglycemia and to 
evaluate the clinical utility of anti -diabetes agents in the management of pasireotide-
induced hyperglycemia.  Preliminary results suggest that pasireotide induces insulin suppression, particularly in the postprandial period, as being the key mechanistic driver of hyperglycemia.   
 Based on the mechanisms of pasireotide- induced hyperglycemia and findings from the 
[SOM230B2124]  study, appropriate management for the pasireotide- induced 
hyperglycemia includes the use of oral anti -diabetic agents for mild to moderate 
hyperglycemia, such as incretin enhancers (e.g. GLP -1analogues or DPP4 inhibitors or 
insulin secretagogues).  Metformin is not recommended.  Insulin should be use d for 
moderate to severe hyperglycemia.   Taking the above into account, hyperglycemia should be monitored and managed according to institutional practice.  
      
09/20 /2017 Page 48  of 61   APPENDIX D: QT Prolonging Medications  
 
The following drugs are generally recognized to have an association with QT 
prolongation.  Thi s list is not conserved to be all inclusive.  
 
Drugs that are generally accepted by [CONTACT_585690].org Advisory Board of the 
Arizona CERT to have a risk of causing torsade de pointes are listed below  
 
Generic Name  [CONTACT_585698]®  Anti-anginal / heart pain  
Amiodarone  Cordarone®  Anti-arrhythmic / abnormal heart 
rhythm  
Amiodarone  Pacerone®  Anti-arrhythmic / abnormal heart 
rhythm  
Disopyramide  Norpace®  Anti-arrhythmic / abnormal heart 
rhythm  
Dofetilide  Tikosyn®  Anti-arrhythmic /  abnormal heart 
rhythm  
Ibutilide  Corvert®  Anti-arrhythmic / abnormal heart 
rhythm  
Procainamide  Pronestyl®  Anti-arrhythmic / abnormal heart 
rhythm  
Procainamide  Procan®  Anti-arrhythmic / abnormal heart 
rhythm  
Quinidine  Cardioquin®  Anti-arrhythmic / abnormal heart 
rhythm  
Quinidine  Quinaglute®  Anti-arrhythmic / abnormal heart 
rhythm  
Sotalol  Betapace®  Anti-arrhythmic / abnormal heart 
rhythm  
Clarithromycin  Biaxin®  Antibiotic / bacterial  infection  
Sparfloxacin  Zagam®  Antibiotic / bacterial infection  
Erythromycin  Erythrocin®  Antibiotic;GI stimulant / bacterial 
infection; increase GI motility  
Erythromycin  E.E.S.®  Antibiotic;GI stimulant / bacterial 
infection; increase GI motility  
Arsenic trioxide  Trisenox®  Anti-cancer / Leukemia  
Astemizole  Hismanal®  Antihistamine / Allergic rhinitis  
Terfenadine  Seldane®  Antihistamine / Allergic rhinitis  
Pentamidine  Pentam® Anti-infective / pneumocystis 
pneumonia  
Pentamidine  NebuPent®  Anti-infective / pneumocystis 
pneumonia  
Probucol  Lorelco®  Antilipemic / 
Hypercholesterolemia  
Chloroquine  Aralen®  Anti-malarial / malaria infection  
Halofantrine  Halfan®  Anti-malarial / malaria infection  
Domperidone  Motilium®  Anti-nausea / nausea  
Mesoridazine  Serentil®  Anti-psychotic / schizophrenia  
Thioridazine  Mellaril®  Anti-psychotic / schizophrenia  
09/20 /2017 Page 49  of 61   Haloperidol  Haldol®  Anti-psychotic / schizophrenia, 
agitation  
Pi[INVESTIGATOR_31930]®  Anti-psychotic / Tourette's tics  
Chlorpromazine  Thorazine®  Anti-psychotic/ Anti -emetic / 
schizophrenia/ nausea  
Cisapride  Propulsid®  GI stimulant / heartburn  
Levomethadyl  Orlaam® Opi[INVESTIGATOR_48489] / pain control, 
narcotic dependence  
Methadone  Dolophine®  Opi[INVESTIGATOR_48489] / pain control, 
narcotic dependence  
Methadone  Methadose®  Opi[INVESTIGATOR_48489] / pain control, 
narcotic dependence  
Droperidol  Inapsine®  Sedative;Anti -nausea / 
anesthesia adjunct, nausea  
 
                         
  
09/20 /2017 Page 50  of 61   APPENDIX  E: Study Drugs and Example Preparatory Regimens  
 
The following is only an example of transplant preparatory regimen that can be used on 
this trial, however, any regimen that meets the definition of myeloablative as defined in 
this protocol is acceptable (TBI ≥ 1200 cGy, or Busulfan ≥ 12.8mg/kg). Similarly, GVHD prophylaxis (e.g. cyclosporine) may be as per institutional standard.  
 E1.  Total Body Irradiation  
Source: Total body irradiation will be delivered in a fractionated fashion over four days in a total of 8 fractions at 150 cGy per fraction to a total of 12 Gy using a Varian Linear Accelerator.  
 Toxicity:  Acute - myelosuppression, complete ablation is expected in the setting of 
bone marrow transplantation.  Severe nausea and vomiting, anorexia, diarrhea, alopecia, fever and mucositis, are common. Pulmonary fibrosis has also been reported. LFTs elevation can also be observed.  
 
E2. Busulfan (Myerlan) NSC #750  
Source and Pharmacology: Alkylating agent utilized intravenously.  The drug is 
metabolized to several metabolites that are excreted into the urine.  Approximately 25% to 35% of busulfan is eliminated via the kidneys as methanesulf onic acid.  Busulfan has 
an elimination half -life around 2.5 hours.  
 Formulation:  IV formulation.  
  Storage and Stability:  Check manufacturer's expi[INVESTIGATOR_320].  Store at room 
temperature.  
 Supplier:  Commercially available from Otsuka.  
 Toxicity:  Acute DLT - myelosuppression, primarily leukopenia, with a nadir of 8- 14 
days; complete ablation is expected in the setting of bone marrow transplantation.  Nausea and vomiting, anorexia, diarrhea, alopecia, fever, mucositis, and hyperpi[INVESTIGATOR_585664].  Liver dysfunction (increased LFTs) and renal or bladder dysfunction (increased BUN, creatinine, necrosis) may be seen.  Pulmonary fibrosis has also been reported.  Peripheral neuropathies and paresthesias have been occasionally observed.  Seizures may occur  in patients receiving busulfan therapy; all 
patients in this study should be prophylaxed with phenytoin (diphenylhydantoin).   
 Route of Administration: IV preparation  
 E3. Cyclophosphamide  (Cytoxan, CTX) NSC #[ZIP_CODE]
 
Source and Pharmacology:   An alkylating  agent, related to nitrogen mustard, which is 
biochemically inert until it is metabolized to its active components by [CONTACT_585691].  It is non- phase- specific.  The drug is excreted exclusively by [CONTACT_585692].  The plasma half -life ranges from 4- 6.5 hours.   
09/20 /2017 Page 51  of 61    
Formulation and Stability:  A freeze- dried powder available in 100 mg and 500 mg vials 
with diluent which contains 0.9% benzyl alcohol in water.  The unreconstituted form of the drug is stable at room temperature for at least [ADDRESS_770257] a slight haze should be discarded.   
 Supplier:  Commercially available.  
 Toxicity:  Acute DLT - myelosuppression, primarily leukopenia, with a nadir of 8- 14 
days; complete ablation is expected in the setting of bone marrow transplantation.  Hemorrhagic cystitis is a potential complication, especially of high- dose therapy.  All 
patients receiving high- dose CTX should have a three- way foley catheter with 
continuous irrigation in place for the duration of CTX therapy and [ADDRESS_770258] foley catheter, a regular 
foley catheter should be used and continuous bladder irrigation can be omitted.  Other adverse reactions include anorexia, nausea and vomiting, alopecia, fluid retention, hyponatremia, inappropriate ADH, immunosuppression, and gonadal suppression with associated sterility.  Pulmonary fibrosis is rare.  Very high doses over a short period of time may be associated with myocardial necrosis, transiently blurred vision, and cardiac toxicity w ith arrhythmias.  Consideration to holding a dose of CTX should be given for 
patients who develop otherwise unexplained tachycardia or a drop in QRS voltage of >25% during cyclophosphamide administration.  
 Route of Administration:  The total daily dose will be given as a 1 -hour IV infusion in 
D5NS.  Patients should receive additional hydration with 3000 ml/m2/day of appropriate 
maintenance IV fluids.   
 E4. Cyclosporine (Sandimmune)
 
Source and Pharmacology:  A cyclic polypeptide immunosuppressant agent consisting of [ADDRESS_770259] is incomplete and variable.  Peak concentrations (C max) in blood 
and plasma are achieved at about 3.5 hours.  The disposition of cyclosporine from blood is biphasic with a terminal half -life of approximately 19 hours (range: 10- 27 
hours).  Elimination is primarily biliary with only 6% of the dose excreted in the urine.  
 Formulation and Stability:  Oral solution in 50 ml bottles (100 mg/ml), soft gelatin capsules (25 mg and 100 mg/capsule), and IV 5 ml ampoules (50 mg/ml).  Store at room temperature.  The oral cyclosporine is in an olive oil solution which should be utilized within two months after the bottle is opened.  It may be mixed in whole milk, 
09/20 /2017 Page 52  of 61   chocolate milk, or fruit juice to mask the taste and should be taken immediately after 
mixing.  The IV solution should be mixed in D5W to a concentration o f 2.5-10 mg/ml and 
should be used within 24 hours after mixing.  
 Supplier:  Commercially available from Sandoz Pharmaceuticals.  
 Toxicity:  Renal dysfunction; increased blood pressure; hirsutism; tremors or seizures; paresthesias; liver toxicity; hyperkalemia or hypokalemia; low serum magnesium; gastrointestinal complaints including anorexia, nausea, and ileus; pancytopenia; gingival hyperplasia; skin pi[INVESTIGATOR_16576]; mental depression; capi[INVESTIGATOR_12737]; lymphoproliferative disorders (malignant lymphoma)  
 Route of Administration:  Continuous IV infusion, or PO at treating physician’s discretion.    
Precautions :  Nephrotoxicity is felt to be related to whole blood drug level and for that 
reason whole blood samples will be obtained at least 3 times  weekly (Monday, 
Wednesday, and Friday) throughout the first [ADDRESS_770260] -transplant (or until switched 
to PO therapy) for the determination of cyclosporine levels.  Blood samples must be obtained from a line which is not in use for constant infusion of cyclosporine.  The whole blood cyclosporine level should not be <100 ng/ml and/or >300 ng/ml.  Another guide to cyclosporine dosing can be assessed by [CONTACT_585693].  The cyclosporine dose should be reduced by 25% if the serum creatinine is between 1.5- 1.7 mg%.  The 
dose should be further reduced 50% if the creatinine is 1.8- 2.0 mg% and the drug held if 
the serum creatinine is >2.0 mg%.  Furthermore the drug dose may need to be modified in patients with liver disease, significant grand mal tremors, significant pancytopenia, and poorly -controlled hypertension.  Cyclosporine therapy may be restarted when the 
whole blood drug level is <300 ng/ml and the serum creatinine returns to treatable levels.  
E5. Methotrexate (MTX)  
MTX is an analog of aminopterin, the folic acid antagonist introduced in 1948 for the treatment of acute leukemia. As one of the antimetabolites, it functions as a decoy substrate for critical biochemical reactions leading to cell death. The amino group substitution found in MTX resul ts in a less potent antifolate but a drug with more 
predictable toxicity profile and equivalent clinical results. The precise mechanism by [CONTACT_585694]; however, it is likely related to MTX’s ability to inhibit cellular growth and division. Therefore, antigen activated T cells that are rapi[INVESTIGATOR_585665]. MTX can induce tolerance following marrow transplantation. In canine transplantation, MTX given after the graft was ef fective in controlling GVHD and in inducing tolerance when donor 
and recipi[INVESTIGATOR_585666].  
 Pharmacology  
MTX was one of the first chemotherapy agents introduced for the therapy of malignancies. Studies have detailed its pharmacokinetics and mechanisms of action at 
the intracellular level. How these mechanisms translate to its in vivo  effects and how it 
09/20 /[ADDRESS_770261] by [CONTACT_366031] (DHFR). DHFR is the intracellular enzyme responsible for converting folic acid to reduced folate cofactors. The reduced state of the folates, namely the tetrahydrofolates are responsible for the transport of single carbon groups that are required for purine and thymidylate synthesis. Once the single carbon group is delivered, the oxidized folates must be converted back to tetrahydrofolates by [CONTACT_585695]. MTX binds to DHFR, thereby [CONTACT_585696].  
 Administration  
Following the administration of MTX approximately 50% is bound to plasma proteins, especially albumin,  with the highest tissue- plasma equilibrium reported in the kidney, 
liver, GI tract and muscle. The GI tract is an important site of distribution and metabolism of MTX, perhaps accounting for one of the primary sites of toxicity. One concern in using MTX i s its clearance in those patients who have pleural or ascitic fluid 
since these reservoir spaces can have a substantial impact on the disposition of MTX. These spaces can be a reservoir from which MTX can be continuously released, leading to severe toxicity. At the low IV doses, MTX clearance correlates with glomerular filtration and renal excretion of unmetabolized drug is the major route for elimination.  
 Polyglutamate formation is also important to MTX metabolism. The formation of MTX polyglutamates intracellularly may account for its retention within the cell and its cytotoxic effects. The enzyme folyl polyglutamate synthetase adds glutamate residues to folates or antifolates such as MTX. These polyglutamate moieties are then retained inside the cell leading to prolonged antifolate activity. The polyglutamate derivatives of MTX appear to be as toxic to DHFR as the native compound. If the retained MTX polyglutamates are produced differentially in lymphocytes compared to other normal cells, the effective co ncentrations of the drug would differ. For example, these 
differences in intracellular concentrations may account for selective toxicities and may selectively inhibit certain subpopulations of cells.  
 Toxicity  
The most common adverse effects of MTX when used for GVHD prophylaxis are hematopoietic, renal, hepatic, and GI mucosal toxicity. Patients may have an elevation in creatinine and elevation of bilirubin levels following the administration of MTX. As many of these are also the side- effects of CSP or tac rolimus, dose attenuation of MTX 
and CSP or tacrolimus may be necessary. Full target doses may not be achievable in patients with grade III -IV mucositis resulting from the preparatory regimen because of 
airway obstruction and severe oropharyngeal bleeding.  
 Clinical use  
The use of MTX following allogeneic BMT has been exclusively with the IV formulation. The drug doses administered have been relatively small given the inability to dose escalate MTX significantly. Initial studies in Seattle tested MTX as a s ingle agent on a 
09/20 /2017 Page 54  of 61   weekly basis up to day +100 but, because of the toxicity of weekly administration of 
MTX, the dose was changed to four doses and combined with CSP. MTX, when used with CSP or tacrolimus, generally is injected IV on days +1, +3, +6 and +11 following 
BMT.  
E6. Example Schedule  
 TBI/Cytoxan  Busulfan/Cytoxan  
Day Treatment  Treatment  
-8 Hickman at 0700  
TBI X 1 (150 cGy)  Admit 9200  
Start Busulfan 12 am  
0.8 mg/kg IV Q6hrs X 16 doses  
-7 TBI X 2 (150 cGy each)  Busulfan Q6hrs  
-6 TBI X 2 (150 cGy each)  Busulfan Q6hrs  
-5 TBI X 2 (150 cGy each)  Busulfan Q6hrs last dose 6 pm  
-4 TBI X 2 (150 cGy each)  Cyclophosphamide 60/mg/kg  
-3 Cytoxan 60 mg/kg  Cyclophosphamide 60 mg/kg  
-2 Cytotoxan 60 mg/kg  Rest 
-[ADDRESS_770262] 
0 Stem Cell Infusion  Stem cells infused  
   
09/20 /2017 Page 55  of 61   APPENDIX  F: Acute GVHD Scoring  
 
Acute GVHD Scoring (BMT CTN, 2013)  
 
 
 
 
  

09/20 /2017 Page 56  of 61   APPENDIX  G: Chronic GVHD Scoring  
 
Chronic GVHD: 2014 NIH Consensus Criteria (Jagasia et. al., 2014)  
 Organ Scoring 
                                           SCORE 0  SCORE 1  SCORE 2  SCORE 3  
PERFORMANCE 
SCORE : _____  
 KPS  
 ECOG  
 LPS    Asymptomatic 
and fully active 
(ECOG 0; KPS or 
LPS 100%)   Symptomatic, 
fully ambulatory, 
restricted only in 
physically strenuous 
activity (ECOG 1, 
KPS or LPS 80 -90%)   Symptomatic, 
ambulatory, capable 
of self -care, >50% of 
waking hours out of 
bed (ECOG 2, KPS or 
LPS 60 -70%)   Symptomatic, 
limited self -care, 
>50% of waking 
hours in bed (ECOG 
3-4, KPS or LPS 
<60%)  
SKIN†  
SCORE % BSA:  _____  
GVHD features to be 
scored  
by [CONTACT_47735]:  
Check all that 
applies:  
  Maculopapular 
rash/erythema  
 Lichen planus -like 
features  
  Sclerotic features  
  Papulosquamous 
lesions or  
ichthyosis  
  Keratosis pi[INVESTIGATOR_22785] -
like GVHD    No BSA involved    1-18% BSA    19-50% BSA    >50% BSA  
SKIN FEATURES  
SCORE: _____   No sclerotic 
features    Superficial  
sclerotic features “not 
hidebound” (able to 
pi[INVESTIGATOR_820])  Check all that 
applies:  
  Deep sclerotic 
features  
  “Hidebound” 
(unable to pi[INVESTIGATOR_820])  
  Impaired mobility  
  Ulceration  
Other skin GVHD features (NOT scored by [CONTACT_47735] )  
Check all that applies:  
  Hyperpi[INVESTIGATOR_585667] -GVHD documented cause 
(specify):_____________________________  
 
† Skin scoring should use both percentage of BSA involved by [CONTACT_91644]. When a 
discrepancy exists between the percentage of total body surface (BSA) score and the skin feature score, OR if superficial sclerotic features are present (Score 2), but there is impaired mobility or ulceration (Score 3), the higher level should be used for the final skin scoring.  
 
09/20 /2017 Page 57  of 61    SCORE 0  SCORE 1  SCORE 2  SCORE 3  
MOUTH  
Lichen planus -like 
features present:  
  Yes  
  No    No symptoms    Mild symptoms 
with diseas e signs but 
not limiting oral 
intake significantly    Moderate 
symptoms with 
disease signs with 
partial limitation of 
oral intake    Severe symptoms 
with disease signs on 
examination with 
major limitation of 
oral intake  
  Abnormality present but explained entirely by [CONTACT_105] -GVHD documented cause 
(specify):_____________________________  
 
                                        SCORE 0  SCORE 1  SCORE 2  SCORE 3  
EYES  
Keratoconjunctivitis 
sicca (KCS) 
confirmed by 
[CONTACT_585697]:  
  Yes  
  No    No symptoms    Mild dry eye 
symptoms not 
affecting ADL 
(requirement of 
lubricant eye drops < 3 x per day)    Moderate dry eye 
symptoms parti ally 
affecting ADL 
(requiring lubricant 
eye drops > 3 x per day or punctal plugs), WITHOUT new 
vision impairment 
due to KCS    Severe dry eye 
symptoms 
significantly affecting 
ADL (special eyeware to relieve pain) OR 
unable to work 
because of ocular 
symptoms OR loss of 
vision due to KCS  
  Abnormality present but explained entirely by [CONTACT_105] -GVHD documented cause 
(specify):_____________________________  
 SCORE [ADDRESS_770263]  
Check all that 
applies:  
   Esophageal web/ 
proximal stricture or 
ring  
  Dysphagia  
  Anorexia  
  Nausea  
  Vomiting  
  Diarrhea  
  Weight loss*  
  Failure to thrive    No symptoms    Symptoms 
without significant 
weight loss* (<5%)  
     
 
  *within last 3 months    Symptoms 
associated with mild 
to moderate weight 
loss* (5 -15%)  
    
 
  *within last 3 months    Symptoms 
associated with 
significant weight 
loss* >15%, requires 
nutritional supplement 
for mos t calorie needs 
or esophageal dilation  
 
 
 *within last 3 months  
  Abnormality present but explained entirely by [CONTACT_105] -GVHD documented cause 
(specify):_____________________________  
 SCORE 0  SCORE 1  SCORE 2  SCORE 3  
LIVER    Normal total 
bilirubin and ALT < 2 
x NUL    Normal total 
bilirubin and ALT >2 
x NUL    Elevated total 
Bilirubin but <3 
mg/dL NUL    Elevated total 
bilirubin > 3 x NUL  
 Abnormality present but explained entirely by [CONTACT_105] -GVHD documented cause 
(specify):_____________________________  
 SCORE 0  SCORE 1  SCORE 2  SCORE 3  
LUNGS**  
Symptoms score :___   No symptoms    Mild symptoms 
(shortness of breath 
after climbing one 
flight of steps)    Moderate 
symptoms (shortness 
of breath after 
walking on flat 
ground)    Severe symptoms 
(shortness of breath at rest; requiring 0
2)  
Lung obstructive 
function score: ____  
FEV1: ____    FEV1≥80 %    FEV1 60 -79    FEV1 40 -59%    FEV1 <39%  
Pulmonary function tests: ____  
09/20 /2017 Page 58  of 61    Not performed  
  Abnormality present but explained entirely by [CONTACT_105] -GVHD documented cause 
(specify):_____________________________  
**Lung scoring should be performed using both the symptoms and FEV1 scores whenever possible. FEV1 should be used 
in the final lung scoring where there is discrepancy between symptoms and FEV1 scores.  
 
                                       SCORE 0  SCORE 1  SCORE 2  SCORE 3  
JOINTS AND FASCIA  
P-ROM score   
Shoulder (1- 7):___  
Elbow (1 -7): ____  
Wrist/finger (1 -
7):___  
Ankle (1 -4):___  
 
P-ROM Chart    No symptoms    Mild tightness of 
arms or legs, normal 
or mild decreased 
range of motion 
(ROM) AND not 
affecting ADL   Tightness of 
arms or legs OR 
joint contractures, 
erythema thought 
due to fasciitis, 
moderate decrease 
ROM AND mild to 
moderate limitation 
of ADL    Contractures WITH 
significant decrease of 
ROM AND significant 
limitation of ADL (unable 
to tie shoes, button shirts, 
dress self etc.)  
 
  Abnormality present but explained entirely by [CONTACT_105] -GVHD documented cause 
(specify):__________________________  
  SCORE [ADDRESS_770264]  
(See Supplemental 
table ‡)  
Check all that 
applies  
 Not examined  
Currently sexually 
active  
  Yes  
  No    No signs    Mild signs ‡ and 
females with or 
without discomfort 
on exam    Moderate signs ‡ 
and may have signs* 
of discomfort on 
exam    Severe signs ‡ with or 
without symptoms  
09/20 /2017 Page 59  of 61   Check all signs that apply:  
 Lichen planus- like features  
 Lichen sclerosis -like features  
 Vaginal scarring (female)  
 Clitoral/labial agglutination (female)  
 Labial resorption (fem ale)  
 Erosions  
 Fissures  
 Ulcers  
 Phimosis (male)  
 Urethral meatus scarring/ stenosis (male)  
 
Female genitalia: Severity of signs:  
1) Mild  (any of the following); erythema on vulvar mucosal surfaces, vulvar lichen -planus or vulvar lichen- sclerosis  
2) Moderate (any of the following); erosive inflammatory changes of the vulvar mucosa, fissures in vulvar folds  
3) Severe (any of the following) ; labial fusion, clitoral hood agglutination, fibrinous vaginal adhesions, 
circumferential  
fibrous vaginal banding, vaginal shortening, synechia, dense sclerotic changes, and complete vaginal stenosis  
Male genitalia: Diagnostic features include lichen planus -like or lichen sclerosis -like features and phymosis or 
urethral scarring or stenosis. Severity of signs: Mild – lichen planus -like feature; Moderate – lichen sclerosis -like 
feature or moderate erythema; Severe – phimosis or urethral/meatal scarring  
 Abnormality present but NOT thought to represent GVHD  
(specify cause):________________________________  
 Abnormality thought to represent GVHD PLUS other causes  
(specify cause):_______________________________  
 
 
Other indicators, clinical features or complications related to chronic GVHD (check all that apply and assign a 
score to its severity (0 -3) based on its functional impact where applicable none – 0,mild -1, moderate -2, severe – 3)  
  Ascites (serositis)___    Myasthenia Gravis___  
  Pericardial Effusion___    Peripheral Neuropathy___    Eosinophilia > 500μl___  
  Pleural Effusion(s)___    Polymyositis___    Platelets <100,000/μl ___  
  Nephrotic syndrome___    Weight loss* without GI 
symptoms    Others 
(specify):_________________  
Overall GVHD 
Severity  
(Opi[INVESTIGATOR_585668])   
 No GVHD  
  
 Mild 
  
 Moderate  
  
 Severe  
 
 
Mild chronic GVHD Moderate chronic GVHD  Severe chronic GVHD  
1or 2 organs involved (not lung) 
plus  
Score in involved organs [ADDRESS_770265] 1 organ (not lung) with a 
score of [ADDRESS_770266] 1 organ with a score of 3  
OR  
Lung score of 2 or 3  
 
  
 
09/20 /2017 Page 60  of 61   Appendix H: SAE Report Coversheets  
 
  
 
 
 
Interventional Clinical Trial SAE F ax Cover Sheet  
 
To: Local [COMPANY_001] Drug Safety and Epi[INVESTIGATOR_585669] 1-[ADDRESS_770267] details:  
Fax number : ____________________________ __ 
Phone number : ____________________________  
 
Study Name   
[CONTACT_343521] N umber   
Patient Number   
  
Relationship between study treatment and event (s) is:  
 
Suspected/Unknown  
   
Investigator Signature   
 
[CONTACT_585699].  
If fax is received in error, please forward to  [PHONE_12144]  
 

09/20 /2017 Page 61  of 61     Version 1.0, 01_Jul_2010  
 
 
 
  Interventional Clinical Trial SAE F ax Cover Sheet  
 
To: Local [COMPANY_001] Drug Safety and Epi[INVESTIGATOR_585669] 1-[ADDRESS_770268] details:  
Fax number : ____________________________ __ 
Phone number : ____________________________  
 
Study Name   
[CONTACT_585700] (s) is:  
 
Not Suspected 
   
Investigator Signature   
[CONTACT_585699].  
If fax is received in error, please forward to  [PHONE_12144]  
 
 
